Evidence Based Medicine on FHIR Implementation Guide
1.0.0-ballot - ballot
Evidence Based Medicine on FHIR Implementation Guide
1.0.0-ballot - ballot
Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 1.0.0-ballot built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions
| Active as of 2024-05-16 |
<Citation xmlns="http://hl7.org/fhir">
<id value="179624"/>
<meta>
<versionId value="1"/>
<lastUpdated value="2023-11-26T22:35:20.060Z"/>
</meta>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p><b>Generated Narrative: Citation</b><a name="179624"> </a><a name="hc179624"> </a></p><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px">ResourceCitation "179624" Version "1" Updated "2023-11-26 22:35:20+0000" </p></div><p><b>url</b>: <code>https://fevir.net/resources/Citation/179624</code></p><p><b>identifier</b>: FEvIR Object Identifier/179624, <code>https://pubmed.ncbi.nlm.nih.gov</code>/24598155</p><p><b>version</b>: 1.0.0-ballot</p><p><b>title</b>: 24598155 Long-term results of a phase II study with neoadjuvant docetaxel chemotherapy and complete androgen blockade in locally advanced and high-risk prostate cancer.</p><p><b>status</b>: active</p><p><b>date</b>: 2024-05-16 12:17:54+0000</p><p><b>publisher</b>: HL7 International / Clinical Decision Support</p><p><b>contact</b>: HL7 International / Clinical Decision Support: <a href="http://www.hl7.org/Special/committees/dss">http://www.hl7.org/Special/committees/dss</a></p><p><b>description</b>: This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide.</p><h3>UseContexts</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Code</b></td><td><b>Value[x]</b></td></tr><tr><td style="display: none">*</td><td>FEvIR Platform Use (Details: Citation Classification Type code fevir-platform-use = 'FEvIR Platform Use', stated as 'FEvIR Platform Use')</td><td>Medline Base <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html">Citation Artifact Classifier</a>#medline-base)</span></td></tr></table><p><b>jurisdiction</b>: World <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (m49.htm#001)</span></p><p><b>copyright</b>: https://creativecommons.org/licenses/by-nc-sa/4.0/</p><p><b>approvalDate</b>: 2015-01-02</p><p><b>lastReviewDate</b>: 2021-10-21</p><p><b>author</b>: Computable Publishing®: MEDLINE-to-FEvIR Converter: </p><blockquote><p><b>classification</b></p><p><b>type</b>: Citation Source <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-classification-type.html">Citation Classification Type</a>#citation-source)</span></p><p><b>classifier</b>: MEDLINE <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p></blockquote><blockquote><p><b>classification</b></p><p><b>type</b>: MEDLINE Citation Owner <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-classification-type.html">Citation Classification Type</a>#medline-owner)</span></p><p><b>classifier</b>: National Library of Medicine, Index Section <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (elements_descriptions.html#owner_value#NLM)</span></p></blockquote><p><b>currentState</b>: Medline Citation Status of Medline <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-status-type.html">Citation Status Type</a>#medline-medline)</span>, PubMed PublicationStatus of epublish <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-status-type.html">Citation Status Type</a>#pubmed-publication-status-epublish)</span></p><blockquote><p><b>statusDate</b></p><p><b>activity</b>: PubMed Pubstatus of Received <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-status-type.html">Citation Status Type</a>#pubmed-pubstatus-received)</span></p><p><b>period</b>: ?? --> 2013-12-27</p></blockquote><blockquote><p><b>statusDate</b></p><p><b>activity</b>: PubMed Pubstatus of Accepted <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-status-type.html">Citation Status Type</a>#pubmed-pubstatus-accepted)</span></p><p><b>period</b>: ?? --> 2014-02-25</p></blockquote><blockquote><p><b>statusDate</b></p><p><b>activity</b>: PubMed Pubstatus of Entrez <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-status-type.html">Citation Status Type</a>#pubmed-pubstatus-entrez)</span></p><p><b>period</b>: ?? --> 2014-03-07 06:00:00+0000</p></blockquote><blockquote><p><b>statusDate</b></p><p><b>activity</b>: PubMed Pubstatus of Pubmed <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-status-type.html">Citation Status Type</a>#pubmed-pubstatus-pubmed)</span></p><p><b>period</b>: ?? --> 2014-03-07 06:00:00+0000</p></blockquote><blockquote><p><b>statusDate</b></p><p><b>activity</b>: PubMed Pubstatus of Medline <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-status-type.html">Citation Status Type</a>#pubmed-pubstatus-medline)</span></p><p><b>period</b>: ?? --> 2015-01-03 06:00:00+0000</p></blockquote><blockquote><p><b>citedArtifact</b></p><p><b>identifier</b>: <code>https://pubmed.ncbi.nlm.nih.gov</code>/24598155, <code>https://www.ncbi.nlm.nih.gov/pmc/</code>/PMC3974001, <code>https://doi.org</code>/10.1186/1756-8722-7-20, pii/1756-8722-7-20</p><h3>Titles</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Type</b></td><td><b>Language</b></td><td><b>Text</b></td></tr><tr><td style="display: none">*</td><td>Primary title <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-title-type.html">Title Type</a>#primary)</span></td><td>English <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://terminology.hl7.org/5.5.0/CodeSystem-v3-ietf3066.html">Tags for the Identification of Languages</a>#en)</span></td><td>Long-term results of a phase II study with neoadjuvant docetaxel chemotherapy and complete androgen blockade in locally advanced and high-risk prostate cancer.</td></tr></table><h3>Abstracts</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Text</b></td></tr><tr><td style="display: none">*</td><td>**BACKGROUND:** Patients with locally advanced and high-risk prostate cancer (LAPC) are prone to experience biochemical recurrence despite radical prostatectomy (RP). We evaluated feasibility, safety and activity of a neoadjuvant chemohormonal therapy (NCHT) with 3-weekly full dose docetaxel and complete androgen blockade (CAB) in locally advanced and high-risk prostate cancer patients (LAPC) undergoing RP.
**METHODS:** Patients (n = 30) were selected by Kattans' preoperative score and received trimestral buserelin 9,45 mg, bicalutamide 50 mg/day and 3 cycles docetaxel (75 mg/m²) followed by RP. Primary endpoints were biochemical (PSA) and local downstaging. Secondary endpoints included toxicity and operability assessments, pathological complete response (pCR), time to PSA progression, 5-year biochemical recurrence free survival (bRFS) and overall survival (OS).
**RESULTS:** Median baseline PSA was 25.8 ng/ml (2.1-293), and the predicted probability of 5-year bRFS was 10% (0-55). NCHT induced PSA-reduction was 97.3% (81.3-99.9%; p &lt; 0.001) and post-RP 96.7% of patients were therapy responders, with undetectable PSA-values. Post- vs. pretreatment MRI indicated a median tumor volume reduction of 46.4% (-31.3-82.8; p &lt; 0.001). A pathological downstaging was observed in 48.3%. Severe hematologic toxicities (≥CTC3) were frequent with 53.8% leucopenia, 90% neutropenia and 13.3% febrile neutropenia. RP was performed in all patients. While resectability was hindered in 26.7%, continence was achieved in 96.7%. Pathologic analyses revealed no pCR. Lymph node- and extracapsular involvement was observed in 36.7% and 56.7% with 33.3% positive surgical margins. After a median of 48.6 (19.9-87.8) months, 55.2% of therapy responders experienced PSA-recurrence. The estimated median time to PSA-progression was 38.6 months (95%CI 30.9-46.4) and 85.3 months (95%CI 39.3-131.3) for OS. The 5-year bRFS was improved to 40%, but limiting for interpretation adjuvant treatment was individualized.
**CONCLUSIONS:** NCHT is feasible despite high hematotoxicity, with excellent functional results. Significant downstaging was observed without pCR. NCHT seems to improve the cohort adjusted 5-year bRFS, but clinical value needs further investigation in randomized trials.</td></tr></table><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: Journal Article <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html">Citation Artifact Classifier</a>#D016428)</span></p><p><b>citation</b>: Kattan MW, Eastham JA, Stapleton AMF, Wheeler TM, Scardino PT. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst. 1998;90:766–771. doi: 10.1093/jnci/90.10.766.</p><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/9605647/">https://pubmed.ncbi.nlm.nih.gov/9605647/</a></td></tr></table><p><b>resourceReference</b>: <span><code>https://pubmed.ncbi.nlm.nih.gov</code>/9605647</span></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: Journal Article <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html">Citation Artifact Classifier</a>#D016428)</span></p><p><b>citation</b>: D’Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, Tomaszewski JE, Renshaw AA, Kaplan I, Beard CJ, Wein A. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280(11):969–974. doi: 10.1001/jama.280.11.969.</p><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/9749478/">https://pubmed.ncbi.nlm.nih.gov/9749478/</a></td></tr></table><p><b>resourceReference</b>: <span><code>https://pubmed.ncbi.nlm.nih.gov</code>/9749478</span></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: Journal Article <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html">Citation Artifact Classifier</a>#D016428)</span></p><p><b>citation</b>: Sonpavde G, Sternberg CN. Neoadjuvant systemic therapy for urological malignancies. BJU Int. 2010;106(1):6–22.</p><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/20553475/">https://pubmed.ncbi.nlm.nih.gov/20553475/</a></td></tr></table><p><b>resourceReference</b>: <span><code>https://pubmed.ncbi.nlm.nih.gov</code>/20553475</span></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: Journal Article <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html">Citation Artifact Classifier</a>#D016428)</span></p><p><b>citation</b>: Bolla M, Collette L, Blank L, Warde P, Dubois JB, Mirimanoff RO, Storme G, Bernier J, Kuten A, Sternberg C, Mattelaer J, Lopez Torecilla J, Pfeffer JR, Lino Cutajar C, Zurlo A, Pierart M. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet. 2002;360(9327):103–106. doi: 10.1016/S0140-6736(02)09408-4.</p><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/12126818/">https://pubmed.ncbi.nlm.nih.gov/12126818/</a></td></tr></table><p><b>resourceReference</b>: <span><code>https://pubmed.ncbi.nlm.nih.gov</code>/12126818</span></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: Journal Article <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html">Citation Artifact Classifier</a>#D016428)</span></p><p><b>citation</b>: Warde P, Mason M, Ding K, Kirkbride P, Brundage M, Cowan R, Gospodarowicz M, Sanders K, Kostashuk E, Swanson G, Barber J, Hiltz A, Parmar MK, Sathya J, Anderson J, Hayter C, Hetherington J, Sydes MR, Parulekar W, NCIC CTG. PR.3/MRC UK PR07 investigators. Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial. Lancet. 2011;378(9809):2104–2111. doi: 10.1016/S0140-6736(11)61095-7.</p><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/22056152/">https://pubmed.ncbi.nlm.nih.gov/22056152/</a></td></tr></table><p><b>resourceReference</b>: <span><code>https://pubmed.ncbi.nlm.nih.gov</code>/22056152</span></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: Journal Article <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html">Citation Artifact Classifier</a>#D016428)</span></p><p><b>citation</b>: Shelley MD, Kumar S, Wilt T, Staffurth J, Coles B, Mason MD. A systematic review and meta-analysis of randomised trials of neo-adjuvant hormone therapy for localised and locally advanced prostate carcinoma. Cancer Treat Rev. 2009;35(1):9–17. doi: 10.1016/j.ctrv.2008.08.002.</p><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/18926640/">https://pubmed.ncbi.nlm.nih.gov/18926640/</a></td></tr></table><p><b>resourceReference</b>: <span><code>https://pubmed.ncbi.nlm.nih.gov</code>/18926640</span></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: Journal Article <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html">Citation Artifact Classifier</a>#D016428)</span></p><p><b>citation</b>: Prayer-Galetti T, Sacco E, Pagano F, Gardiman M, Cisternino A, Betto G, Sperandio P. Long-term follow-up of a neoadjuvant chemohormonal taxane-based phase II trial before radical prostatectomy in patients with non-metastatic high-risk prostate cancer. BJU Int. 2007;100(2):274–280. doi: 10.1111/j.1464-410X.2007.06760.x.</p><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/17355369/">https://pubmed.ncbi.nlm.nih.gov/17355369/</a></td></tr></table><p><b>resourceReference</b>: <span><code>https://pubmed.ncbi.nlm.nih.gov</code>/17355369</span></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: Journal Article <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html">Citation Artifact Classifier</a>#D016428)</span></p><p><b>citation</b>: Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351(15):1513–1520. doi: 10.1056/NEJMoa041318.</p><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/15470214/">https://pubmed.ncbi.nlm.nih.gov/15470214/</a></td></tr></table><p><b>resourceReference</b>: <span><code>https://pubmed.ncbi.nlm.nih.gov</code>/15470214</span></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: Journal Article <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html">Citation Artifact Classifier</a>#D016428)</span></p><p><b>citation</b>: Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol. 2008;26(2):242–245. doi: 10.1200/JCO.2007.12.4008.</p><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/18182665/">https://pubmed.ncbi.nlm.nih.gov/18182665/</a></td></tr></table><p><b>resourceReference</b>: <span><code>https://pubmed.ncbi.nlm.nih.gov</code>/18182665</span></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: Journal Article <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html">Citation Artifact Classifier</a>#D016428)</span></p><p><b>citation</b>: Sartor AO. Progression of metastatic castrate-resistant prostate cancer: impact of therapeutic intervention in the post-docetaxel space. J Hematol Oncol. 2011;4:18. doi: 10.1186/1756-8722-4-18.</p><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/21513551/">https://pubmed.ncbi.nlm.nih.gov/21513551/</a></td></tr></table><p><b>resourceReference</b>: <span><code>https://pubmed.ncbi.nlm.nih.gov</code>/21513551</span></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: Journal Article <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html">Citation Artifact Classifier</a>#D016428)</span></p><p><b>citation</b>: Huang X, Chau CH, Figg WD. Challenges to improved therapeutics for metastatic castrate resistant prostate cancer: from recent successes and failures. J Hematol Oncol. 2012;5:35. doi: 10.1186/1756-8722-5-35.</p><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/22747660/">https://pubmed.ncbi.nlm.nih.gov/22747660/</a></td></tr></table><p><b>resourceReference</b>: <span><code>https://pubmed.ncbi.nlm.nih.gov</code>/22747660</span></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: Journal Article <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html">Citation Artifact Classifier</a>#D016428)</span></p><p><b>citation</b>: Dreicer R, Magi-Galluzzi C, Zhou M, Rothaermel J, Reuther A, Ulchaker J, Zippe C, Fergany A, Klein EA. Phase II trial of neoadjuvant docetaxel before radical prostatectomy for locally advanced prostate cancer. Urology. 2004;63(6):1138–1142. doi: 10.1016/j.urology.2004.01.040.</p><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/15183967/">https://pubmed.ncbi.nlm.nih.gov/15183967/</a></td></tr></table><p><b>resourceReference</b>: <span><code>https://pubmed.ncbi.nlm.nih.gov</code>/15183967</span></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: Journal Article <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html">Citation Artifact Classifier</a>#D016428)</span></p><p><b>citation</b>: Febbo PG, Richie JP, George DJ, Loda M, Manola J, Shankar S, Barnes AS, Tempany C, Catalona W, Kantoff PW, Oh WK. Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer. Clin Cancer Res. 2005;11(14):5233–5240. doi: 10.1158/1078-0432.CCR-05-0299.</p><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/16033841/">https://pubmed.ncbi.nlm.nih.gov/16033841/</a></td></tr></table><p><b>resourceReference</b>: <span><code>https://pubmed.ncbi.nlm.nih.gov</code>/16033841</span></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: Journal Article <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html">Citation Artifact Classifier</a>#D016428)</span></p><p><b>citation</b>: Magi-Galluzzi C, Zhou M, Reuther AM, Dreicer R, Klein EA. Neoadjuvant docetaxel treatment for locally advanced prostate cancer: a clinicopathologic study. Cancer. 2007;110(6):1248–1254. doi: 10.1002/cncr.22897.</p><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/17674353/">https://pubmed.ncbi.nlm.nih.gov/17674353/</a></td></tr></table><p><b>resourceReference</b>: <span><code>https://pubmed.ncbi.nlm.nih.gov</code>/17674353</span></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: Journal Article <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html">Citation Artifact Classifier</a>#D016428)</span></p><p><b>citation</b>: Mellado B, Font A, Alcaraz A, Aparicio LA, Veiga FJ, Areal J, Gallardo E, Hannaoui N, Lorenzo JR, Sousa A, Fernandez PL, Gascon P. Phase II trial of short-term neoadjuvant docetaxel and complete androgen blockade in high-risk prostate cancer. Br J Cancer. 2009;101(8):1248–1252. doi: 10.1038/sj.bjc.6605320.</p><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/19755998/">https://pubmed.ncbi.nlm.nih.gov/19755998/</a></td></tr></table><p><b>resourceReference</b>: <span><code>https://pubmed.ncbi.nlm.nih.gov</code>/19755998</span></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: Journal Article <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html">Citation Artifact Classifier</a>#D016428)</span></p><p><b>citation</b>: Chi KN, Chin JL, Winquist E, Klotz L, Saad F, Gleave ME. Multicenter phase II study of combined neoadjuvant docetaxel and hormone therapy before radical prostatectomy for patients with high risk localized prostate cancer. J Urol. 2008;180(2):565–570. doi: 10.1016/j.juro.2008.04.012.</p><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/18554663/">https://pubmed.ncbi.nlm.nih.gov/18554663/</a></td></tr></table><p><b>resourceReference</b>: <span><code>https://pubmed.ncbi.nlm.nih.gov</code>/18554663</span></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: Journal Article <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html">Citation Artifact Classifier</a>#D016428)</span></p><p><b>citation</b>: Sella A, Zisman A, Kovel S, Yarom N, Leibovici D, Lindner A. Neoadjuvant chemohormonal therapy in poor-prognosis localized prostate cancer. Urology. 2008;71(2):323–327. doi: 10.1016/j.urology.2007.08.060.</p><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/18308112/">https://pubmed.ncbi.nlm.nih.gov/18308112/</a></td></tr></table><p><b>resourceReference</b>: <span><code>https://pubmed.ncbi.nlm.nih.gov</code>/18308112</span></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: Journal Article <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html">Citation Artifact Classifier</a>#D016428)</span></p><p><b>citation</b>: Narita S, Tsuchiya N, Kumazawa T, Maita S, Numakura K, Obara T, Tsuruta H, Saito M, Inoue T, Horikawa Y, Satoh S, Nanjyo H, Habuchi T. Short-term clinicopathological outcome of neoadjuvant chemohormonal therapy comprising complete androgen blockade, followed by treatment with docetaxel and estramustine phosphate before radical prostatectomy in Japanese patients with high-risk localized prostate cancer. World J Surg Oncol. 2012;10:1. doi: 10.1186/1477-7819-10-1.</p><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/22214417/">https://pubmed.ncbi.nlm.nih.gov/22214417/</a></td></tr></table><p><b>resourceReference</b>: <span><code>https://pubmed.ncbi.nlm.nih.gov</code>/22214417</span></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: Journal Article <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html">Citation Artifact Classifier</a>#D016428)</span></p><p><b>citation</b>: van der Kwast TH, Têtu B, Candas B, Gomez JL, Cusan L, Labrie F. Prolonged neoadjuvant combined androgen blockade leads to a further reduction of prostatic tumor volume: three versus six months of endocrine therapy. Urology. 1999;53(3):523–529. doi: 10.1016/S0090-4295(98)00542-1.</p><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/10096378/">https://pubmed.ncbi.nlm.nih.gov/10096378/</a></td></tr></table><p><b>resourceReference</b>: <span><code>https://pubmed.ncbi.nlm.nih.gov</code>/10096378</span></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: Journal Article <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html">Citation Artifact Classifier</a>#D016428)</span></p><p><b>citation</b>: Hu JC, Elkin EP, Pasta DJ, Lubeck DP, Kattan MW, Carroll PR, Litwin MS. Predicting quality of life after radical prostatectomy: results from CaPSURE. J Urol. 2004;171(2 Pt 1):703–708.</p><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/14713791/">https://pubmed.ncbi.nlm.nih.gov/14713791/</a></td></tr></table><p><b>resourceReference</b>: <span><code>https://pubmed.ncbi.nlm.nih.gov</code>/14713791</span></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: Journal Article <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html">Citation Artifact Classifier</a>#D016428)</span></p><p><b>citation</b>: Kim WY, Whang YE, Pruthi RS, Baggstrom MQ, Rathmell WK, Rosenman JG, Wallen EM, Goyal LK, Grigson G, Watkins C, Godley PA. Neoadjuvant docetaxel/estramustine prior to radical prostatectomy or external beam radiotherapy in high risk localized prostate cancer: a phase II trial. Urol Oncol. 2011;29(6):608–613. doi: 10.1016/j.urolonc.2009.09.012.</p><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/20022268/">https://pubmed.ncbi.nlm.nih.gov/20022268/</a></td></tr></table><p><b>resourceReference</b>: <span><code>https://pubmed.ncbi.nlm.nih.gov</code>/20022268</span></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: Journal Article <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html">Citation Artifact Classifier</a>#D016428)</span></p><p><b>citation</b>: Schulman CC, Debruyne FM, Forster G, Selvaggi FP, Zlotta AR, Witjes WP. 4-year follow-up results of a European prospective randomized study on neoadjuvant hormonal therapy prior to radical prostatectomy in T2-3N0M0 prostate cancer. European Study Group on Neoadjuvant Treatment of Prostate Cancer. Eur Urol. 2000;38(6):706–713. doi: 10.1159/000020366.</p><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/11111188/">https://pubmed.ncbi.nlm.nih.gov/11111188/</a></td></tr></table><p><b>resourceReference</b>: <span><code>https://pubmed.ncbi.nlm.nih.gov</code>/11111188</span></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: Journal Article <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html">Citation Artifact Classifier</a>#D016428)</span></p><p><b>citation</b>: Hussain M, Smith DC, El-Rayes BF, Du W, Vaishampayan U, Fontana J, Sakr W, Wood D. Neoadjuvant docetaxel and estramustine chemotherapy in high-risk/locallyadvanced prostate cancer. Urology. 2003;61(4):774–780. doi: 10.1016/S0090-4295(02)02519-0.</p><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/12670564/">https://pubmed.ncbi.nlm.nih.gov/12670564/</a></td></tr></table><p><b>resourceReference</b>: <span><code>https://pubmed.ncbi.nlm.nih.gov</code>/12670564</span></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: Journal Article <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html">Citation Artifact Classifier</a>#D016428)</span></p><p><b>citation</b>: Eastham JA, Kelly WK, Grossfeld GD, Small EJ. Cancer and Leukemia Group B (CALGB) 90203: a randomized phase 3 study of radical prostatectomy alone versus estramustine and docetaxel before radical prostatectomy for patients with high-risk localized disease. Urology. 2003;62(Suppl 1):55–62.</p><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/14747042/">https://pubmed.ncbi.nlm.nih.gov/14747042/</a></td></tr></table><p><b>resourceReference</b>: <span><code>https://pubmed.ncbi.nlm.nih.gov</code>/14747042</span></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: Journal Article <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html">Citation Artifact Classifier</a>#D016428)</span></p><p><b>citation</b>: D’Amico AV, Chang E, Garnick M, Kantoff P, Jiroutek M, Tempany CM. Assessment of prostate cancer volume using endorectal coil magnetic resonance imaging: a new predictor of tumor response to neoadjuvant androgen suppression therapy. Urology. 1998;51(2):287–292. doi: 10.1016/S0090-4295(97)00610-9.</p><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/9495713/">https://pubmed.ncbi.nlm.nih.gov/9495713/</a></td></tr></table><p><b>resourceReference</b>: <span><code>https://pubmed.ncbi.nlm.nih.gov</code>/9495713</span></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: Journal Article <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html">Citation Artifact Classifier</a>#D016428)</span></p><p><b>citation</b>: D’Amico AV, Halabi S, Tempany C, Titelbaum D, Philips GK, Loffredo M, McMahon E, Sanford B, Vogelzang NJ, Small EJ. Cancer and Leukemia Group B. Tumor volume changes on 1.5 tesla endorectal MRI during neoadjuvant androgen suppression therapy for higher-risk prostate cancer and recurrence in men treated using radiation therapy results of the phase II CALGB 9682 study. Int J Radiat Oncol Biol Phys. 2008;71(1):9–15. doi: 10.1016/j.ijrobp.2007.09.033.</p><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/18037582/">https://pubmed.ncbi.nlm.nih.gov/18037582/</a></td></tr></table><p><b>resourceReference</b>: <span><code>https://pubmed.ncbi.nlm.nih.gov</code>/18037582</span></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: Journal Article <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html">Citation Artifact Classifier</a>#D016428)</span></p><p><b>citation</b>: Vuky J, Porter C, Isacson C, Vaughan M, Kozlowski P, Picozzi V, Corman J. Phase II trial of neoadjuvant docetaxel and gefitinib followed by radical prostatectomy in patients with high-risk, locally advanced prostate cancer. Cancer. 2009;115(4):784–791. doi: 10.1002/cncr.24092.</p><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/19130458/">https://pubmed.ncbi.nlm.nih.gov/19130458/</a></td></tr></table><p><b>resourceReference</b>: <span><code>https://pubmed.ncbi.nlm.nih.gov</code>/19130458</span></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: Journal Article <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html">Citation Artifact Classifier</a>#D016428)</span></p><p><b>citation</b>: Mottet N, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Schmid HP, Van der Kwast T, Wiegel T, Zattoni F, Heidenreich A. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol. 2011;59(4):572–583. doi: 10.1016/j.eururo.2011.01.025.</p><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/21315502/">https://pubmed.ncbi.nlm.nih.gov/21315502/</a></td></tr></table><p><b>resourceReference</b>: <span><code>https://pubmed.ncbi.nlm.nih.gov</code>/21315502</span></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: Journal Article <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html">Citation Artifact Classifier</a>#D016428)</span></p><p><b>citation</b>: Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA. Sildenafil Study Group. Oral sildenafil in the treatment of erectile dysfunction. 1998. J Urol. 2002;167(2 Pt 2):1197–1203.</p><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/11905901/">https://pubmed.ncbi.nlm.nih.gov/11905901/</a></td></tr></table><p><b>resourceReference</b>: <span><code>https://pubmed.ncbi.nlm.nih.gov</code>/11905901</span></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: cites</p><p><b>classifier</b>: Journal Article <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html">Citation Artifact Classifier</a>#D016428)</span></p><p><b>citation</b>: Bubley GJ, Carducci M, Dahut W, Dawson N, Daliani D, Eisenberger M, Figg WD, Freidlin B, Halabi S, Hudes G, Hussain M, Kaplan R, Myers C, Oh W, Petrylak DP, Reed E, Roth B, Sartor O, Scher H, Simons J, Sinibaldi V, Small EJ, Smith MR, Trump DL, Robin V, Wilding G. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol. 1999;17(11):3461–3467.</p><h3>Documents</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Url</b></td></tr><tr><td style="display: none">*</td><td><a href="https://pubmed.ncbi.nlm.nih.gov/10550143/">https://pubmed.ncbi.nlm.nih.gov/10550143/</a></td></tr></table><p><b>resourceReference</b>: <span><code>https://pubmed.ncbi.nlm.nih.gov</code>/10550143</span></p></blockquote><blockquote><p><b>publicationForm</b></p><h3>PublishedIns</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Type</b></td><td><b>Identifier</b></td><td><b>Title</b></td><td><b>PublisherLocation</b></td></tr><tr><td style="display: none">*</td><td>Periodical <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-published-in-type.html">Published In Type</a>#D020492)</span></td><td>Electronic ISSN Type/1756-8722, ISOAbbreviation/J Hematol Oncol, ISSN Linking/1756-8722, Medline Title Abbreviation/J Hematol Oncol, NLM Unique ID/101468937</td><td>Journal of hematology & oncology</td><td>England</td></tr></table><p><b>citedMedium</b>: Internet <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-cited-medium.html">Cited Medium</a>#internet)</span></p><p><b>volume</b>: 7</p><p><b>articleDate</b>: 2014-03-05</p><p><b>publicationDateText</b>: 2014-Mar-05</p><p><b>language</b>: English <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://terminology.hl7.org/5.5.0/CodeSystem-v3-ietf3066.html">Tags for the Identification of Languages</a>#en)</span></p><p><b>pageString</b>: 20</p></blockquote><blockquote><p><b>publicationForm</b></p><p><b>citedMedium</b>: Internet without issue <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-cited-medium.html">Cited Medium</a>#internet-without-issue)</span></p><p><b>articleDate</b>: 2014-03-05</p></blockquote><blockquote><p><b>webLocation</b></p><p><b>classifier</b>: Abstract <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-artifact-url-classifier.html">Artifact Url Classifier</a>#abstract)</span></p><p><b>url</b>: <a href="https://pubmed.ncbi.nlm.nih.gov/24598155/">https://pubmed.ncbi.nlm.nih.gov/24598155/</a></p></blockquote><blockquote><p><b>webLocation</b></p><p><b>classifier</b>: DOI Based <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-artifact-url-classifier.html">Artifact Url Classifier</a>#doi-based)</span></p><p><b>url</b>: <a href="https://doi.org/10.1186/1756-8722-7-20">https://doi.org/10.1186/1756-8722-7-20</a></p></blockquote><blockquote><p><b>classification</b></p><p><b>type</b>: Publishing Model <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html">Cited Artifact Classification Type</a>#publishing-model)</span></p><p><b>classifier</b>: Electronic <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html">Citation Artifact Classifier</a>#Electronic)</span></p></blockquote><blockquote><p><b>classification</b></p><p><b>type</b>: Chemical <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html">Cited Artifact Classification Type</a>#chemical)</span></p><p><b>classifier</b>: Androgen Antagonists <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#D000726)</span>, Taxoids <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#D043823)</span>, Docetaxel <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (chemical-substances#15H5577CQD; #D000077143)</span></p></blockquote><blockquote><p><b>classification</b></p><p><b>type</b>: MeSH Heading <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html">Cited Artifact Classification Type</a>#mesh-heading)</span></p><p><b>artifactAssessment</b>: <a name="hcmeshHeading0"> </a></p><blockquote><p/><p><a name="meshHeading0"> </a></p><p><a name="hcmeshHeading0"> </a></p><p><b>artifact</b>: <a href="#">#</a></p><blockquote><p><b>content</b></p><p><b>informationType</b>: classifier</p><p><b>type</b>: components (if present) include qualifier codings <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html">Cited Artifact Classification Type</a>#mesh-heading "MeSH heading")</span></p><p><b>classifier</b>: Aged <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#D000368)</span></p><p><b>freeToShare</b>: true</p><h3>Components</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style="display: none">*</td><td>qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></td><td>is not a major topic <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></td></tr></table></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: classifier</p><p><b>type</b>: components (if present) include qualifier codings <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html">Cited Artifact Classification Type</a>#mesh-heading "MeSH heading")</span></p><p><b>classifier</b>: Androgen Antagonists <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#D000726)</span></p><p><b>freeToShare</b>: true</p><blockquote><p><b>component</b></p><p><b>type</b>: qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p><p><b>classifier</b>: is not a major topic <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p></blockquote><blockquote><p><b>component</b></p><p><b>type</b>: qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p><p><b>classifier</b>: therapeutic use <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#Q000627)</span></p><blockquote><p><b>component</b></p></blockquote></blockquote></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: classifier</p><p><b>type</b>: components (if present) include qualifier codings <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html">Cited Artifact Classification Type</a>#mesh-heading "MeSH heading")</span></p><p><b>classifier</b>: Disease Progression <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#D018450)</span></p><p><b>freeToShare</b>: true</p><h3>Components</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style="display: none">*</td><td>qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></td><td>is not a major topic <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></td></tr></table></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: classifier</p><p><b>type</b>: components (if present) include qualifier codings <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html">Cited Artifact Classification Type</a>#mesh-heading "MeSH heading")</span></p><p><b>classifier</b>: Docetaxel <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#D000077143)</span></p><p><b>freeToShare</b>: true</p><h3>Components</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style="display: none">*</td><td>qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></td><td>is not a major topic <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></td></tr></table></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: classifier</p><p><b>type</b>: components (if present) include qualifier codings <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html">Cited Artifact Classification Type</a>#mesh-heading "MeSH heading")</span></p><p><b>classifier</b>: Humans <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#D006801)</span></p><p><b>freeToShare</b>: true</p><h3>Components</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style="display: none">*</td><td>qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></td><td>is not a major topic <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></td></tr></table></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: classifier</p><p><b>type</b>: components (if present) include qualifier codings <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html">Cited Artifact Classification Type</a>#mesh-heading "MeSH heading")</span></p><p><b>classifier</b>: Male <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#D008297)</span></p><p><b>freeToShare</b>: true</p><h3>Components</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style="display: none">*</td><td>qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></td><td>is not a major topic <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></td></tr></table></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: classifier</p><p><b>type</b>: components (if present) include qualifier codings <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html">Cited Artifact Classification Type</a>#mesh-heading "MeSH heading")</span></p><p><b>classifier</b>: Middle Aged <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#D008875)</span></p><p><b>freeToShare</b>: true</p><h3>Components</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style="display: none">*</td><td>qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></td><td>is not a major topic <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></td></tr></table></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: classifier</p><p><b>type</b>: components (if present) include qualifier codings <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html">Cited Artifact Classification Type</a>#mesh-heading "MeSH heading")</span></p><p><b>classifier</b>: Neoadjuvant Therapy <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#D020360)</span></p><p><b>freeToShare</b>: true</p><h3>Components</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style="display: none">*</td><td>qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></td><td>is not a major topic <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></td></tr></table></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: classifier</p><p><b>type</b>: components (if present) include qualifier codings <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html">Cited Artifact Classification Type</a>#mesh-heading "MeSH heading")</span></p><p><b>classifier</b>: Prostatic Neoplasms <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#D011471)</span></p><p><b>freeToShare</b>: true</p><blockquote><p><b>component</b></p><p><b>type</b>: qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p><p><b>classifier</b>: is not a major topic <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p></blockquote><blockquote><p><b>component</b></p><p><b>type</b>: qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p><p><b>classifier</b>: drug therapy <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#Q000188)</span></p><blockquote><p><b>component</b></p></blockquote></blockquote><blockquote><p><b>component</b></p><p><b>type</b>: qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p><p><b>classifier</b>: surgery <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#Q000601)</span></p><blockquote><p><b>component</b></p></blockquote></blockquote></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: classifier</p><p><b>type</b>: components (if present) include qualifier codings <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html">Cited Artifact Classification Type</a>#mesh-heading "MeSH heading")</span></p><p><b>classifier</b>: Survival Analysis <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#D016019)</span></p><p><b>freeToShare</b>: true</p><h3>Components</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style="display: none">*</td><td>qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></td><td>is not a major topic <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></td></tr></table></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: classifier</p><p><b>type</b>: components (if present) include qualifier codings <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html">Cited Artifact Classification Type</a>#mesh-heading "MeSH heading")</span></p><p><b>classifier</b>: Taxoids <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#D043823)</span></p><p><b>freeToShare</b>: true</p><blockquote><p><b>component</b></p><p><b>type</b>: qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p><p><b>classifier</b>: is not a major topic <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p></blockquote><blockquote><p><b>component</b></p><p><b>type</b>: qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p><p><b>classifier</b>: adverse effects <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#Q000009)</span></p><blockquote><p><b>component</b></p></blockquote></blockquote><blockquote><p><b>component</b></p><p><b>type</b>: qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p><p><b>classifier</b>: therapeutic use <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#Q000627)</span></p><blockquote><p><b>component</b></p></blockquote></blockquote></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: classifier</p><p><b>type</b>: components (if present) include qualifier codings <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html">Cited Artifact Classification Type</a>#mesh-heading "MeSH heading")</span></p><p><b>classifier</b>: Treatment Outcome <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#D016896)</span></p><p><b>freeToShare</b>: true</p><h3>Components</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style="display: none">*</td><td>qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></td><td>is not a major topic <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></td></tr></table></blockquote></blockquote></blockquote><blockquote><p><b>classification</b></p><p><b>type</b>: Publication Type <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html">Cited Artifact Classification Type</a>#publication-type)</span></p><p><b>classifier</b>: Clinical Trial, Phase II <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#D017427)</span>, Journal Article <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#D016428)</span></p></blockquote><blockquote><p><b>classification</b></p><p><b>type</b>: Knowledge Artifact Type <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html">Cited Artifact Classification Type</a>#knowledge-artifact-type)</span></p><p><b>classifier</b>: Journal Article <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-citation-artifact-classifier.html">Citation Artifact Classifier</a>#D016428)</span></p><p><b>artifactAssessment</b>: <span>: Classifier added by Computable Publishing LLC</span></p></blockquote><blockquote><p><b>classification</b></p><p><b>type</b>: Citation Subset <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html">Cited Artifact Classification Type</a>#citation-subset)</span></p><p><b>classifier</b>: IM <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (elements_descriptions.html#citationsubset#IM)</span></p></blockquote><blockquote><p><b>contributorship</b></p><p><b>complete</b>: true</p><blockquote><p><b>entry</b></p><p><b>contributor</b>: <a name="hcauthor0"> </a></p><blockquote><p/><p><a name="author0"> </a></p><p><a name="hcauthor0"> </a></p><p><b>name</b>: Mark Thalgott </p></blockquote><p><b>forenameInitials</b>: M</p><p><b>affiliation</b>: <span>: Department of Urology, Klinikum rechts der Isar, Technische Universität München, Ismaninger Str, 22, Munich 81675, Germany. mark.thalgott@lrz.tum.de.</span></p></blockquote><blockquote><p><b>entry</b></p><p><b>contributor</b>: <a name="hcauthor1"> </a></p><blockquote><p/><p><a name="author1"> </a></p><p><a name="hcauthor1"> </a></p><p><b>name</b>: Thomas Horn </p></blockquote><p><b>forenameInitials</b>: T</p></blockquote><blockquote><p><b>entry</b></p><p><b>contributor</b>: <a name="hcauthor2"> </a></p><blockquote><p/><p><a name="author2"> </a></p><p><a name="hcauthor2"> </a></p><p><b>name</b>: Matthias M Heck </p></blockquote><p><b>forenameInitials</b>: MM</p></blockquote><blockquote><p><b>entry</b></p><p><b>contributor</b>: <a name="hcauthor3"> </a></p><blockquote><p/><p><a name="author3"> </a></p><p><a name="hcauthor3"> </a></p><p><b>name</b>: Tobias Maurer </p></blockquote><p><b>forenameInitials</b>: T</p></blockquote><blockquote><p><b>entry</b></p><p><b>contributor</b>: <a name="hcauthor4"> </a></p><blockquote><p/><p><a name="author4"> </a></p><p><a name="hcauthor4"> </a></p><p><b>name</b>: Matthias Eiber </p></blockquote><p><b>forenameInitials</b>: M</p></blockquote><blockquote><p><b>entry</b></p><p><b>contributor</b>: <a name="hcauthor5"> </a></p><blockquote><p/><p><a name="author5"> </a></p><p><a name="hcauthor5"> </a></p><p><b>name</b>: Margitta Retz </p></blockquote><p><b>forenameInitials</b>: M</p></blockquote><blockquote><p><b>entry</b></p><p><b>contributor</b>: <a name="hcauthor6"> </a></p><blockquote><p/><p><a name="author6"> </a></p><p><a name="hcauthor6"> </a></p><p><b>name</b>: Michael Autenrieth </p></blockquote><p><b>forenameInitials</b>: M</p></blockquote><blockquote><p><b>entry</b></p><p><b>contributor</b>: <a name="hcauthor7"> </a></p><blockquote><p/><p><a name="author7"> </a></p><p><a name="hcauthor7"> </a></p><p><b>name</b>: Kathleen Herkommer </p></blockquote><p><b>forenameInitials</b>: K</p></blockquote><blockquote><p><b>entry</b></p><p><b>contributor</b>: <a name="hcauthor8"> </a></p><blockquote><p/><p><a name="author8"> </a></p><p><a name="hcauthor8"> </a></p><p><b>name</b>: Bernd J Krause </p></blockquote><p><b>forenameInitials</b>: BJ</p></blockquote><blockquote><p><b>entry</b></p><p><b>contributor</b>: <a name="hcauthor9"> </a></p><blockquote><p/><p><a name="author9"> </a></p><p><a name="hcauthor9"> </a></p><p><b>name</b>: Jürgen E Gschwend </p></blockquote><p><b>forenameInitials</b>: JE</p></blockquote><blockquote><p><b>entry</b></p><p><b>contributor</b>: <a name="hcauthor10"> </a></p><blockquote><p/><p><a name="author10"> </a></p><p><a name="hcauthor10"> </a></p><p><b>name</b>: Uwe Treiber </p></blockquote><p><b>forenameInitials</b>: U</p></blockquote><blockquote><p><b>entry</b></p><p><b>contributor</b>: <a name="hcauthor11"> </a></p><blockquote><p/><p><a name="author11"> </a></p><p><a name="hcauthor11"> </a></p><p><b>name</b>: Hubert R Kübler </p></blockquote><p><b>forenameInitials</b>: HR</p></blockquote></blockquote></blockquote><hr/><blockquote><p><b>Generated Narrative: Practitioner #author0</b><a name="author0"> </a><a name="hcauthor0"> </a></p><p><b>name</b>: Mark Thalgott </p></blockquote><hr/><blockquote><p><b>Generated Narrative: Practitioner #author1</b><a name="author1"> </a><a name="hcauthor1"> </a></p><p><b>name</b>: Thomas Horn </p></blockquote><hr/><blockquote><p><b>Generated Narrative: Practitioner #author2</b><a name="author2"> </a><a name="hcauthor2"> </a></p><p><b>name</b>: Matthias M Heck </p></blockquote><hr/><blockquote><p><b>Generated Narrative: Practitioner #author3</b><a name="author3"> </a><a name="hcauthor3"> </a></p><p><b>name</b>: Tobias Maurer </p></blockquote><hr/><blockquote><p><b>Generated Narrative: Practitioner #author4</b><a name="author4"> </a><a name="hcauthor4"> </a></p><p><b>name</b>: Matthias Eiber </p></blockquote><hr/><blockquote><p><b>Generated Narrative: Practitioner #author5</b><a name="author5"> </a><a name="hcauthor5"> </a></p><p><b>name</b>: Margitta Retz </p></blockquote><hr/><blockquote><p><b>Generated Narrative: Practitioner #author6</b><a name="author6"> </a><a name="hcauthor6"> </a></p><p><b>name</b>: Michael Autenrieth </p></blockquote><hr/><blockquote><p><b>Generated Narrative: Practitioner #author7</b><a name="author7"> </a><a name="hcauthor7"> </a></p><p><b>name</b>: Kathleen Herkommer </p></blockquote><hr/><blockquote><p><b>Generated Narrative: Practitioner #author8</b><a name="author8"> </a><a name="hcauthor8"> </a></p><p><b>name</b>: Bernd J Krause </p></blockquote><hr/><blockquote><p><b>Generated Narrative: Practitioner #author9</b><a name="author9"> </a><a name="hcauthor9"> </a></p><p><b>name</b>: Jürgen E Gschwend </p></blockquote><hr/><blockquote><p><b>Generated Narrative: Practitioner #author10</b><a name="author10"> </a><a name="hcauthor10"> </a></p><p><b>name</b>: Uwe Treiber </p></blockquote><hr/><blockquote><p><b>Generated Narrative: Practitioner #author11</b><a name="author11"> </a><a name="hcauthor11"> </a></p><p><b>name</b>: Hubert R Kübler </p></blockquote><hr/><blockquote><p><b>Generated Narrative: ArtifactAssessment #meshHeading0</b><a name="meshHeading0"> </a><a name="hcmeshHeading0"> </a></p><p><b>artifact</b>: <a href="#">#</a></p><blockquote><p><b>content</b></p><p><b>informationType</b>: classifier</p><p><b>type</b>: components (if present) include qualifier codings <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html">Cited Artifact Classification Type</a>#mesh-heading "MeSH heading")</span></p><p><b>classifier</b>: Aged <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#D000368)</span></p><p><b>freeToShare</b>: true</p><h3>Components</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style="display: none">*</td><td>qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></td><td>is not a major topic <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></td></tr></table></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: classifier</p><p><b>type</b>: components (if present) include qualifier codings <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html">Cited Artifact Classification Type</a>#mesh-heading "MeSH heading")</span></p><p><b>classifier</b>: Androgen Antagonists <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#D000726)</span></p><p><b>freeToShare</b>: true</p><blockquote><p><b>component</b></p><p><b>type</b>: qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p><p><b>classifier</b>: is not a major topic <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p></blockquote><blockquote><p><b>component</b></p><p><b>type</b>: qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p><p><b>classifier</b>: therapeutic use <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#Q000627)</span></p><blockquote><p><b>component</b></p></blockquote></blockquote></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: classifier</p><p><b>type</b>: components (if present) include qualifier codings <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html">Cited Artifact Classification Type</a>#mesh-heading "MeSH heading")</span></p><p><b>classifier</b>: Disease Progression <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#D018450)</span></p><p><b>freeToShare</b>: true</p><h3>Components</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style="display: none">*</td><td>qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></td><td>is not a major topic <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></td></tr></table></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: classifier</p><p><b>type</b>: components (if present) include qualifier codings <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html">Cited Artifact Classification Type</a>#mesh-heading "MeSH heading")</span></p><p><b>classifier</b>: Docetaxel <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#D000077143)</span></p><p><b>freeToShare</b>: true</p><h3>Components</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style="display: none">*</td><td>qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></td><td>is not a major topic <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></td></tr></table></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: classifier</p><p><b>type</b>: components (if present) include qualifier codings <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html">Cited Artifact Classification Type</a>#mesh-heading "MeSH heading")</span></p><p><b>classifier</b>: Humans <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#D006801)</span></p><p><b>freeToShare</b>: true</p><h3>Components</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style="display: none">*</td><td>qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></td><td>is not a major topic <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></td></tr></table></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: classifier</p><p><b>type</b>: components (if present) include qualifier codings <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html">Cited Artifact Classification Type</a>#mesh-heading "MeSH heading")</span></p><p><b>classifier</b>: Male <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#D008297)</span></p><p><b>freeToShare</b>: true</p><h3>Components</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style="display: none">*</td><td>qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></td><td>is not a major topic <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></td></tr></table></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: classifier</p><p><b>type</b>: components (if present) include qualifier codings <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html">Cited Artifact Classification Type</a>#mesh-heading "MeSH heading")</span></p><p><b>classifier</b>: Middle Aged <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#D008875)</span></p><p><b>freeToShare</b>: true</p><h3>Components</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style="display: none">*</td><td>qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></td><td>is not a major topic <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></td></tr></table></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: classifier</p><p><b>type</b>: components (if present) include qualifier codings <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html">Cited Artifact Classification Type</a>#mesh-heading "MeSH heading")</span></p><p><b>classifier</b>: Neoadjuvant Therapy <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#D020360)</span></p><p><b>freeToShare</b>: true</p><h3>Components</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style="display: none">*</td><td>qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></td><td>is not a major topic <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></td></tr></table></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: classifier</p><p><b>type</b>: components (if present) include qualifier codings <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html">Cited Artifact Classification Type</a>#mesh-heading "MeSH heading")</span></p><p><b>classifier</b>: Prostatic Neoplasms <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#D011471)</span></p><p><b>freeToShare</b>: true</p><blockquote><p><b>component</b></p><p><b>type</b>: qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p><p><b>classifier</b>: is not a major topic <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p></blockquote><blockquote><p><b>component</b></p><p><b>type</b>: qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p><p><b>classifier</b>: drug therapy <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#Q000188)</span></p><blockquote><p><b>component</b></p></blockquote></blockquote><blockquote><p><b>component</b></p><p><b>type</b>: qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p><p><b>classifier</b>: surgery <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#Q000601)</span></p><blockquote><p><b>component</b></p></blockquote></blockquote></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: classifier</p><p><b>type</b>: components (if present) include qualifier codings <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html">Cited Artifact Classification Type</a>#mesh-heading "MeSH heading")</span></p><p><b>classifier</b>: Survival Analysis <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#D016019)</span></p><p><b>freeToShare</b>: true</p><h3>Components</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style="display: none">*</td><td>qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></td><td>is not a major topic <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></td></tr></table></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: classifier</p><p><b>type</b>: components (if present) include qualifier codings <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html">Cited Artifact Classification Type</a>#mesh-heading "MeSH heading")</span></p><p><b>classifier</b>: Taxoids <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#D043823)</span></p><p><b>freeToShare</b>: true</p><blockquote><p><b>component</b></p><p><b>type</b>: qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p><p><b>classifier</b>: is not a major topic <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p></blockquote><blockquote><p><b>component</b></p><p><b>type</b>: qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p><p><b>classifier</b>: adverse effects <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#Q000009)</span></p><blockquote><p><b>component</b></p></blockquote></blockquote><blockquote><p><b>component</b></p><p><b>type</b>: qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></p><p><b>classifier</b>: therapeutic use <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#Q000627)</span></p><blockquote><p><b>component</b></p></blockquote></blockquote></blockquote><blockquote><p><b>content</b></p><p><b>informationType</b>: classifier</p><p><b>type</b>: components (if present) include qualifier codings <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://hl7.org/fhir/R5/codesystem-cited-artifact-classification-type.html">Cited Artifact Classification Type</a>#mesh-heading "MeSH heading")</span></p><p><b>classifier</b>: Treatment Outcome <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#D016896)</span></p><p><b>freeToShare</b>: true</p><h3>Components</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style="display: none">*</td><td>qualifier <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></td><td>is not a major topic <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ()</span></td></tr></table></blockquote></blockquote></div>
</text>
<contained>
<Practitioner>
<id value="author0"/>
<name>
<family value="Thalgott"/>
<given value="Mark"/>
</name>
</Practitioner>
</contained>
<contained>
<Practitioner>
<id value="author1"/>
<name>
<family value="Horn"/>
<given value="Thomas"/>
</name>
</Practitioner>
</contained>
<contained>
<Practitioner>
<id value="author2"/>
<name>
<family value="Heck"/>
<given value="Matthias M"/>
</name>
</Practitioner>
</contained>
<contained>
<Practitioner>
<id value="author3"/>
<name>
<family value="Maurer"/>
<given value="Tobias"/>
</name>
</Practitioner>
</contained>
<contained>
<Practitioner>
<id value="author4"/>
<name>
<family value="Eiber"/>
<given value="Matthias"/>
</name>
</Practitioner>
</contained>
<contained>
<Practitioner>
<id value="author5"/>
<name>
<family value="Retz"/>
<given value="Margitta"/>
</name>
</Practitioner>
</contained>
<contained>
<Practitioner>
<id value="author6"/>
<name>
<family value="Autenrieth"/>
<given value="Michael"/>
</name>
</Practitioner>
</contained>
<contained>
<Practitioner>
<id value="author7"/>
<name>
<family value="Herkommer"/>
<given value="Kathleen"/>
</name>
</Practitioner>
</contained>
<contained>
<Practitioner>
<id value="author8"/>
<name>
<family value="Krause"/>
<given value="Bernd J"/>
</name>
</Practitioner>
</contained>
<contained>
<Practitioner>
<id value="author9"/>
<name>
<family value="Gschwend"/>
<given value="Jürgen E"/>
</name>
</Practitioner>
</contained>
<contained>
<Practitioner>
<id value="author10"/>
<name>
<family value="Treiber"/>
<given value="Uwe"/>
</name>
</Practitioner>
</contained>
<contained>
<Practitioner>
<id value="author11"/>
<name>
<family value="Kübler"/>
<given value="Hubert R"/>
</name>
</Practitioner>
</contained>
<contained>
<ArtifactAssessment>
<id value="meshHeading0"/>
<artifactReference>
<reference value="#"/>
<type value="Citation"/>
</artifactReference>
<content>
<informationType value="classifier"/>
<type>
<coding>
<system
value="http://hl7.org/fhir/cited-artifact-classification-type"/>
<code value="mesh-heading"/>
<display value="MeSH heading"/>
</coding>
<text value="components (if present) include qualifier codings"/>
</type>
<classifier>
<coding>
<system value="https://meshb.nlm.nih.gov/"/>
<code value="D000368"/>
<display value="Aged"/>
<userSelected value="false"/>
</coding>
</classifier>
<freeToShare value="true"/>
<component>
<type>
<text value="qualifier"/>
</type>
<classifier>
<text value="is not a major topic"/>
</classifier>
</component>
</content>
<content>
<informationType value="classifier"/>
<type>
<coding>
<system
value="http://hl7.org/fhir/cited-artifact-classification-type"/>
<code value="mesh-heading"/>
<display value="MeSH heading"/>
</coding>
<text value="components (if present) include qualifier codings"/>
</type>
<classifier>
<coding>
<system value="https://meshb.nlm.nih.gov/"/>
<code value="D000726"/>
<display value="Androgen Antagonists"/>
<userSelected value="false"/>
</coding>
</classifier>
<freeToShare value="true"/>
<component>
<type>
<text value="qualifier"/>
</type>
<classifier>
<text value="is not a major topic"/>
</classifier>
</component>
<component>
<type>
<text value="qualifier"/>
</type>
<classifier>
<coding>
<system value="https://meshb.nlm.nih.gov/"/>
<code value="Q000627"/>
<display value="therapeutic use"/>
</coding>
</classifier>
<component>
<type>
<text value="is Major topic"/>
</type>
<classifier>
<coding>
<system value="https://ncithesaurus.nci.nih.gov/ncitbrowser"/>
<code value="C49488"/>
<display value="Yes"/>
</coding>
</classifier>
</component>
</component>
</content>
<content>
<informationType value="classifier"/>
<type>
<coding>
<system
value="http://hl7.org/fhir/cited-artifact-classification-type"/>
<code value="mesh-heading"/>
<display value="MeSH heading"/>
</coding>
<text value="components (if present) include qualifier codings"/>
</type>
<classifier>
<coding>
<system value="https://meshb.nlm.nih.gov/"/>
<code value="D018450"/>
<display value="Disease Progression"/>
<userSelected value="false"/>
</coding>
</classifier>
<freeToShare value="true"/>
<component>
<type>
<text value="qualifier"/>
</type>
<classifier>
<text value="is not a major topic"/>
</classifier>
</component>
</content>
<content>
<informationType value="classifier"/>
<type>
<coding>
<system
value="http://hl7.org/fhir/cited-artifact-classification-type"/>
<code value="mesh-heading"/>
<display value="MeSH heading"/>
</coding>
<text value="components (if present) include qualifier codings"/>
</type>
<classifier>
<coding>
<system value="https://meshb.nlm.nih.gov/"/>
<code value="D000077143"/>
<display value="Docetaxel"/>
<userSelected value="false"/>
</coding>
</classifier>
<freeToShare value="true"/>
<component>
<type>
<text value="qualifier"/>
</type>
<classifier>
<text value="is not a major topic"/>
</classifier>
</component>
</content>
<content>
<informationType value="classifier"/>
<type>
<coding>
<system
value="http://hl7.org/fhir/cited-artifact-classification-type"/>
<code value="mesh-heading"/>
<display value="MeSH heading"/>
</coding>
<text value="components (if present) include qualifier codings"/>
</type>
<classifier>
<coding>
<system value="https://meshb.nlm.nih.gov/"/>
<code value="D006801"/>
<display value="Humans"/>
<userSelected value="false"/>
</coding>
</classifier>
<freeToShare value="true"/>
<component>
<type>
<text value="qualifier"/>
</type>
<classifier>
<text value="is not a major topic"/>
</classifier>
</component>
</content>
<content>
<informationType value="classifier"/>
<type>
<coding>
<system
value="http://hl7.org/fhir/cited-artifact-classification-type"/>
<code value="mesh-heading"/>
<display value="MeSH heading"/>
</coding>
<text value="components (if present) include qualifier codings"/>
</type>
<classifier>
<coding>
<system value="https://meshb.nlm.nih.gov/"/>
<code value="D008297"/>
<display value="Male"/>
<userSelected value="false"/>
</coding>
</classifier>
<freeToShare value="true"/>
<component>
<type>
<text value="qualifier"/>
</type>
<classifier>
<text value="is not a major topic"/>
</classifier>
</component>
</content>
<content>
<informationType value="classifier"/>
<type>
<coding>
<system
value="http://hl7.org/fhir/cited-artifact-classification-type"/>
<code value="mesh-heading"/>
<display value="MeSH heading"/>
</coding>
<text value="components (if present) include qualifier codings"/>
</type>
<classifier>
<coding>
<system value="https://meshb.nlm.nih.gov/"/>
<code value="D008875"/>
<display value="Middle Aged"/>
<userSelected value="false"/>
</coding>
</classifier>
<freeToShare value="true"/>
<component>
<type>
<text value="qualifier"/>
</type>
<classifier>
<text value="is not a major topic"/>
</classifier>
</component>
</content>
<content>
<informationType value="classifier"/>
<type>
<coding>
<system
value="http://hl7.org/fhir/cited-artifact-classification-type"/>
<code value="mesh-heading"/>
<display value="MeSH heading"/>
</coding>
<text value="components (if present) include qualifier codings"/>
</type>
<classifier>
<coding>
<system value="https://meshb.nlm.nih.gov/"/>
<code value="D020360"/>
<display value="Neoadjuvant Therapy"/>
<userSelected value="false"/>
</coding>
</classifier>
<freeToShare value="true"/>
<component>
<type>
<text value="qualifier"/>
</type>
<classifier>
<text value="is not a major topic"/>
</classifier>
</component>
</content>
<content>
<informationType value="classifier"/>
<type>
<coding>
<system
value="http://hl7.org/fhir/cited-artifact-classification-type"/>
<code value="mesh-heading"/>
<display value="MeSH heading"/>
</coding>
<text value="components (if present) include qualifier codings"/>
</type>
<classifier>
<coding>
<system value="https://meshb.nlm.nih.gov/"/>
<code value="D011471"/>
<display value="Prostatic Neoplasms"/>
<userSelected value="false"/>
</coding>
</classifier>
<freeToShare value="true"/>
<component>
<type>
<text value="qualifier"/>
</type>
<classifier>
<text value="is not a major topic"/>
</classifier>
</component>
<component>
<type>
<text value="qualifier"/>
</type>
<classifier>
<coding>
<system value="https://meshb.nlm.nih.gov/"/>
<code value="Q000188"/>
<display value="drug therapy"/>
</coding>
</classifier>
<component>
<type>
<text value="is Major topic"/>
</type>
<classifier>
<coding>
<system value="https://ncithesaurus.nci.nih.gov/ncitbrowser"/>
<code value="C49488"/>
<display value="Yes"/>
</coding>
</classifier>
</component>
</component>
<component>
<type>
<text value="qualifier"/>
</type>
<classifier>
<coding>
<system value="https://meshb.nlm.nih.gov/"/>
<code value="Q000601"/>
<display value="surgery"/>
</coding>
</classifier>
<component>
<type>
<text value="is Major topic"/>
</type>
<classifier>
<coding>
<system value="https://ncithesaurus.nci.nih.gov/ncitbrowser"/>
<code value="C49487"/>
<display value="No"/>
</coding>
</classifier>
</component>
</component>
</content>
<content>
<informationType value="classifier"/>
<type>
<coding>
<system
value="http://hl7.org/fhir/cited-artifact-classification-type"/>
<code value="mesh-heading"/>
<display value="MeSH heading"/>
</coding>
<text value="components (if present) include qualifier codings"/>
</type>
<classifier>
<coding>
<system value="https://meshb.nlm.nih.gov/"/>
<code value="D016019"/>
<display value="Survival Analysis"/>
<userSelected value="false"/>
</coding>
</classifier>
<freeToShare value="true"/>
<component>
<type>
<text value="qualifier"/>
</type>
<classifier>
<text value="is not a major topic"/>
</classifier>
</component>
</content>
<content>
<informationType value="classifier"/>
<type>
<coding>
<system
value="http://hl7.org/fhir/cited-artifact-classification-type"/>
<code value="mesh-heading"/>
<display value="MeSH heading"/>
</coding>
<text value="components (if present) include qualifier codings"/>
</type>
<classifier>
<coding>
<system value="https://meshb.nlm.nih.gov/"/>
<code value="D043823"/>
<display value="Taxoids"/>
<userSelected value="false"/>
</coding>
</classifier>
<freeToShare value="true"/>
<component>
<type>
<text value="qualifier"/>
</type>
<classifier>
<text value="is not a major topic"/>
</classifier>
</component>
<component>
<type>
<text value="qualifier"/>
</type>
<classifier>
<coding>
<system value="https://meshb.nlm.nih.gov/"/>
<code value="Q000009"/>
<display value="adverse effects"/>
</coding>
</classifier>
<component>
<type>
<text value="is Major topic"/>
</type>
<classifier>
<coding>
<system value="https://ncithesaurus.nci.nih.gov/ncitbrowser"/>
<code value="C49487"/>
<display value="No"/>
</coding>
</classifier>
</component>
</component>
<component>
<type>
<text value="qualifier"/>
</type>
<classifier>
<coding>
<system value="https://meshb.nlm.nih.gov/"/>
<code value="Q000627"/>
<display value="therapeutic use"/>
</coding>
</classifier>
<component>
<type>
<text value="is Major topic"/>
</type>
<classifier>
<coding>
<system value="https://ncithesaurus.nci.nih.gov/ncitbrowser"/>
<code value="C49488"/>
<display value="Yes"/>
</coding>
</classifier>
</component>
</component>
</content>
<content>
<informationType value="classifier"/>
<type>
<coding>
<system
value="http://hl7.org/fhir/cited-artifact-classification-type"/>
<code value="mesh-heading"/>
<display value="MeSH heading"/>
</coding>
<text value="components (if present) include qualifier codings"/>
</type>
<classifier>
<coding>
<system value="https://meshb.nlm.nih.gov/"/>
<code value="D016896"/>
<display value="Treatment Outcome"/>
<userSelected value="false"/>
</coding>
</classifier>
<freeToShare value="true"/>
<component>
<type>
<text value="qualifier"/>
</type>
<classifier>
<text value="is not a major topic"/>
</classifier>
</component>
</content>
</ArtifactAssessment>
</contained>
<url value="https://fevir.net/resources/Citation/179624"/>
<identifier>
<type>
<coding>
<system value="http://terminology.hl7.org/CodeSystem/v2-0203"/>
<code value="ACSN"/>
<display value="Accession ID"/>
</coding>
<text value="FEvIR Object Identifier"/>
</type>
<system value="https://fevir.net"/>
<value value="179624"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<identifier>
<system value="https://pubmed.ncbi.nlm.nih.gov"/>
<value value="24598155"/>
</identifier>
<version value="1.0.0-ballot"/>
<title
value="24598155 Long-term results of a phase II study with neoadjuvant docetaxel chemotherapy and complete androgen blockade in locally advanced and high-risk prostate cancer."/>
<status value="active"/>
<date value="2024-05-16T12:17:54+00:00"/>
<publisher value="HL7 International / Clinical Decision Support"/>
<contact>
<name value="HL7 International / Clinical Decision Support"/>
<telecom>
<system value="url"/>
<value value="http://www.hl7.org/Special/committees/dss"/>
</telecom>
</contact>
<description
value="This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide."/>
<useContext>
<code>
<system value="http://hl7.org/fhir/citation-classification-type"/>
<code value="fevir-platform-use"/>
<display value="FEvIR Platform Use"/>
</code>
<valueCodeableConcept>
<coding>
<system value="http://hl7.org/fhir/citation-artifact-classifier"/>
<code value="medline-base"/>
<display value="Medline Base"/>
<userSelected value="false"/>
</coding>
</valueCodeableConcept>
</useContext>
<jurisdiction>
<coding>
<system value="http://unstats.un.org/unsd/methods/m49/m49.htm"/>
<code value="001"/>
<display value="World"/>
</coding>
</jurisdiction>
<copyright value="https://creativecommons.org/licenses/by-nc-sa/4.0/"/>
<approvalDate value="2015-01-02"/>
<lastReviewDate value="2021-10-21"/>
<author>
<name value="Computable Publishing®: MEDLINE-to-FEvIR Converter"/>
</author>
<classification>
<type>
<coding>
<system value="http://hl7.org/fhir/citation-classification-type"/>
<code value="citation-source"/>
<display value="Citation Source"/>
</coding>
</type>
<classifier>
<text value="MEDLINE"/>
</classifier>
</classification>
<classification>
<type>
<coding>
<system value="http://hl7.org/fhir/citation-classification-type"/>
<code value="medline-owner"/>
<display value="MEDLINE Citation Owner"/>
</coding>
</type>
<classifier>
<coding>
<system
value="https://www.nlm.nih.gov/bsd/licensee/elements_descriptions.html#owner_value"/>
<code value="NLM"/>
<display value="National Library of Medicine, Index Section"/>
<userSelected value="false"/>
</coding>
</classifier>
</classification>
<currentState>
<coding>
<system value="http://hl7.org/fhir/citation-status-type"/>
<code value="medline-medline"/>
<display value="Medline Citation Status of Medline"/>
</coding>
</currentState>
<currentState>
<coding>
<system value="http://hl7.org/fhir/citation-status-type"/>
<code value="pubmed-publication-status-epublish"/>
<display value="PubMed PublicationStatus of epublish"/>
</coding>
</currentState>
<statusDate>
<activity>
<coding>
<system value="http://hl7.org/fhir/citation-status-type"/>
<code value="pubmed-pubstatus-received"/>
<display value="PubMed Pubstatus of Received"/>
</coding>
</activity>
<period>
<end value="2013-12-27"/>
</period>
</statusDate>
<statusDate>
<activity>
<coding>
<system value="http://hl7.org/fhir/citation-status-type"/>
<code value="pubmed-pubstatus-accepted"/>
<display value="PubMed Pubstatus of Accepted"/>
</coding>
</activity>
<period>
<end value="2014-02-25"/>
</period>
</statusDate>
<statusDate>
<activity>
<coding>
<system value="http://hl7.org/fhir/citation-status-type"/>
<code value="pubmed-pubstatus-entrez"/>
<display value="PubMed Pubstatus of Entrez"/>
</coding>
</activity>
<period>
<end value="2014-03-07T06:00:00.000Z"/>
</period>
</statusDate>
<statusDate>
<activity>
<coding>
<system value="http://hl7.org/fhir/citation-status-type"/>
<code value="pubmed-pubstatus-pubmed"/>
<display value="PubMed Pubstatus of Pubmed"/>
</coding>
</activity>
<period>
<end value="2014-03-07T06:00:00.000Z"/>
</period>
</statusDate>
<statusDate>
<activity>
<coding>
<system value="http://hl7.org/fhir/citation-status-type"/>
<code value="pubmed-pubstatus-medline"/>
<display value="PubMed Pubstatus of Medline"/>
</coding>
</activity>
<period>
<end value="2015-01-03T06:00:00.000Z"/>
</period>
</statusDate>
<citedArtifact>
<identifier>
<system value="https://pubmed.ncbi.nlm.nih.gov"/>
<value value="24598155"/>
</identifier>
<identifier>
<system value="https://www.ncbi.nlm.nih.gov/pmc/"/>
<value value="PMC3974001"/>
</identifier>
<identifier>
<system value="https://doi.org"/>
<value value="10.1186/1756-8722-7-20"/>
</identifier>
<identifier>
<type>
<coding>
<system value="http://terminology.hl7.org/CodeSystem/v2-0203"/>
<code value="ACSN"/>
<display value="Accession ID"/>
</coding>
<text value="pii"/>
</type>
<value value="1756-8722-7-20"/>
</identifier>
<title>
<type>
<coding>
<system value="http://hl7.org/fhir/title-type"/>
<code value="primary"/>
<display value="Primary title"/>
</coding>
</type>
<language>
<coding>
<system value="urn:ietf:bcp:47"/>
<code value="en"/>
<display value="English"/>
</coding>
</language>
<text
value="Long-term results of a phase II study with neoadjuvant docetaxel chemotherapy and complete androgen blockade in locally advanced and high-risk prostate cancer."/>
</title>
<abstract>
<text
value="**BACKGROUND:** Patients with locally advanced and high-risk prostate cancer (LAPC) are prone to experience biochemical recurrence despite radical prostatectomy (RP). We evaluated feasibility, safety and activity of a neoadjuvant chemohormonal therapy (NCHT) with 3-weekly full dose docetaxel and complete androgen blockade (CAB) in locally advanced and high-risk prostate cancer patients (LAPC) undergoing RP.
**METHODS:** Patients (n = 30) were selected by Kattans' preoperative score and received trimestral buserelin 9,45 mg, bicalutamide 50 mg/day and 3 cycles docetaxel (75 mg/m²) followed by RP. Primary endpoints were biochemical (PSA) and local downstaging. Secondary endpoints included toxicity and operability assessments, pathological complete response (pCR), time to PSA progression, 5-year biochemical recurrence free survival (bRFS) and overall survival (OS).
**RESULTS:** Median baseline PSA was 25.8 ng/ml (2.1-293), and the predicted probability of 5-year bRFS was 10% (0-55). NCHT induced PSA-reduction was 97.3% (81.3-99.9%; p &lt; 0.001) and post-RP 96.7% of patients were therapy responders, with undetectable PSA-values. Post- vs. pretreatment MRI indicated a median tumor volume reduction of 46.4% (-31.3-82.8; p &lt; 0.001). A pathological downstaging was observed in 48.3%. Severe hematologic toxicities (≥CTC3) were frequent with 53.8% leucopenia, 90% neutropenia and 13.3% febrile neutropenia. RP was performed in all patients. While resectability was hindered in 26.7%, continence was achieved in 96.7%. Pathologic analyses revealed no pCR. Lymph node- and extracapsular involvement was observed in 36.7% and 56.7% with 33.3% positive surgical margins. After a median of 48.6 (19.9-87.8) months, 55.2% of therapy responders experienced PSA-recurrence. The estimated median time to PSA-progression was 38.6 months (95%CI 30.9-46.4) and 85.3 months (95%CI 39.3-131.3) for OS. The 5-year bRFS was improved to 40%, but limiting for interpretation adjuvant treatment was individualized.
**CONCLUSIONS:** NCHT is feasible despite high hematotoxicity, with excellent functional results. Significant downstaging was observed without pCR. NCHT seems to improve the cohort adjusted 5-year bRFS, but clinical value needs further investigation in randomized trials."/>
</abstract>
<relatesTo>
<type value="cites"/>
<classifier>
<coding>
<system value="http://hl7.org/fhir/citation-artifact-classifier"/>
<code value="D016428"/>
<display value="Journal Article"/>
</coding>
</classifier>
<citation
value="Kattan MW, Eastham JA, Stapleton AMF, Wheeler TM, Scardino PT. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst. 1998;90:766–771. doi: 10.1093/jnci/90.10.766."/>
<document>
<url value="https://pubmed.ncbi.nlm.nih.gov/9605647/"/>
</document>
<resourceReference>
<identifier>
<system value="https://pubmed.ncbi.nlm.nih.gov"/>
<value value="9605647"/>
<assigner>
<display value="NLM"/>
</assigner>
</identifier>
</resourceReference>
</relatesTo>
<relatesTo>
<type value="cites"/>
<classifier>
<coding>
<system value="http://hl7.org/fhir/citation-artifact-classifier"/>
<code value="D016428"/>
<display value="Journal Article"/>
</coding>
</classifier>
<citation
value="D’Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, Tomaszewski JE, Renshaw AA, Kaplan I, Beard CJ, Wein A. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280(11):969–974. doi: 10.1001/jama.280.11.969."/>
<document>
<url value="https://pubmed.ncbi.nlm.nih.gov/9749478/"/>
</document>
<resourceReference>
<identifier>
<system value="https://pubmed.ncbi.nlm.nih.gov"/>
<value value="9749478"/>
<assigner>
<display value="NLM"/>
</assigner>
</identifier>
</resourceReference>
</relatesTo>
<relatesTo>
<type value="cites"/>
<classifier>
<coding>
<system value="http://hl7.org/fhir/citation-artifact-classifier"/>
<code value="D016428"/>
<display value="Journal Article"/>
</coding>
</classifier>
<citation
value="Sonpavde G, Sternberg CN. Neoadjuvant systemic therapy for urological malignancies. BJU Int. 2010;106(1):6–22."/>
<document>
<url value="https://pubmed.ncbi.nlm.nih.gov/20553475/"/>
</document>
<resourceReference>
<identifier>
<system value="https://pubmed.ncbi.nlm.nih.gov"/>
<value value="20553475"/>
<assigner>
<display value="NLM"/>
</assigner>
</identifier>
</resourceReference>
</relatesTo>
<relatesTo>
<type value="cites"/>
<classifier>
<coding>
<system value="http://hl7.org/fhir/citation-artifact-classifier"/>
<code value="D016428"/>
<display value="Journal Article"/>
</coding>
</classifier>
<citation
value="Bolla M, Collette L, Blank L, Warde P, Dubois JB, Mirimanoff RO, Storme G, Bernier J, Kuten A, Sternberg C, Mattelaer J, Lopez Torecilla J, Pfeffer JR, Lino Cutajar C, Zurlo A, Pierart M. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet. 2002;360(9327):103–106. doi: 10.1016/S0140-6736(02)09408-4."/>
<document>
<url value="https://pubmed.ncbi.nlm.nih.gov/12126818/"/>
</document>
<resourceReference>
<identifier>
<system value="https://pubmed.ncbi.nlm.nih.gov"/>
<value value="12126818"/>
<assigner>
<display value="NLM"/>
</assigner>
</identifier>
</resourceReference>
</relatesTo>
<relatesTo>
<type value="cites"/>
<classifier>
<coding>
<system value="http://hl7.org/fhir/citation-artifact-classifier"/>
<code value="D016428"/>
<display value="Journal Article"/>
</coding>
</classifier>
<citation
value="Warde P, Mason M, Ding K, Kirkbride P, Brundage M, Cowan R, Gospodarowicz M, Sanders K, Kostashuk E, Swanson G, Barber J, Hiltz A, Parmar MK, Sathya J, Anderson J, Hayter C, Hetherington J, Sydes MR, Parulekar W, NCIC CTG. PR.3/MRC UK PR07 investigators. Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial. Lancet. 2011;378(9809):2104–2111. doi: 10.1016/S0140-6736(11)61095-7."/>
<document>
<url value="https://pubmed.ncbi.nlm.nih.gov/22056152/"/>
</document>
<resourceReference>
<identifier>
<system value="https://pubmed.ncbi.nlm.nih.gov"/>
<value value="22056152"/>
<assigner>
<display value="NLM"/>
</assigner>
</identifier>
</resourceReference>
</relatesTo>
<relatesTo>
<type value="cites"/>
<classifier>
<coding>
<system value="http://hl7.org/fhir/citation-artifact-classifier"/>
<code value="D016428"/>
<display value="Journal Article"/>
</coding>
</classifier>
<citation
value="Shelley MD, Kumar S, Wilt T, Staffurth J, Coles B, Mason MD. A systematic review and meta-analysis of randomised trials of neo-adjuvant hormone therapy for localised and locally advanced prostate carcinoma. Cancer Treat Rev. 2009;35(1):9–17. doi: 10.1016/j.ctrv.2008.08.002."/>
<document>
<url value="https://pubmed.ncbi.nlm.nih.gov/18926640/"/>
</document>
<resourceReference>
<identifier>
<system value="https://pubmed.ncbi.nlm.nih.gov"/>
<value value="18926640"/>
<assigner>
<display value="NLM"/>
</assigner>
</identifier>
</resourceReference>
</relatesTo>
<relatesTo>
<type value="cites"/>
<classifier>
<coding>
<system value="http://hl7.org/fhir/citation-artifact-classifier"/>
<code value="D016428"/>
<display value="Journal Article"/>
</coding>
</classifier>
<citation
value="Prayer-Galetti T, Sacco E, Pagano F, Gardiman M, Cisternino A, Betto G, Sperandio P. Long-term follow-up of a neoadjuvant chemohormonal taxane-based phase II trial before radical prostatectomy in patients with non-metastatic high-risk prostate cancer. BJU Int. 2007;100(2):274–280. doi: 10.1111/j.1464-410X.2007.06760.x."/>
<document>
<url value="https://pubmed.ncbi.nlm.nih.gov/17355369/"/>
</document>
<resourceReference>
<identifier>
<system value="https://pubmed.ncbi.nlm.nih.gov"/>
<value value="17355369"/>
<assigner>
<display value="NLM"/>
</assigner>
</identifier>
</resourceReference>
</relatesTo>
<relatesTo>
<type value="cites"/>
<classifier>
<coding>
<system value="http://hl7.org/fhir/citation-artifact-classifier"/>
<code value="D016428"/>
<display value="Journal Article"/>
</coding>
</classifier>
<citation
value="Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351(15):1513–1520. doi: 10.1056/NEJMoa041318."/>
<document>
<url value="https://pubmed.ncbi.nlm.nih.gov/15470214/"/>
</document>
<resourceReference>
<identifier>
<system value="https://pubmed.ncbi.nlm.nih.gov"/>
<value value="15470214"/>
<assigner>
<display value="NLM"/>
</assigner>
</identifier>
</resourceReference>
</relatesTo>
<relatesTo>
<type value="cites"/>
<classifier>
<coding>
<system value="http://hl7.org/fhir/citation-artifact-classifier"/>
<code value="D016428"/>
<display value="Journal Article"/>
</coding>
</classifier>
<citation
value="Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol. 2008;26(2):242–245. doi: 10.1200/JCO.2007.12.4008."/>
<document>
<url value="https://pubmed.ncbi.nlm.nih.gov/18182665/"/>
</document>
<resourceReference>
<identifier>
<system value="https://pubmed.ncbi.nlm.nih.gov"/>
<value value="18182665"/>
<assigner>
<display value="NLM"/>
</assigner>
</identifier>
</resourceReference>
</relatesTo>
<relatesTo>
<type value="cites"/>
<classifier>
<coding>
<system value="http://hl7.org/fhir/citation-artifact-classifier"/>
<code value="D016428"/>
<display value="Journal Article"/>
</coding>
</classifier>
<citation
value="Sartor AO. Progression of metastatic castrate-resistant prostate cancer: impact of therapeutic intervention in the post-docetaxel space. J Hematol Oncol. 2011;4:18. doi: 10.1186/1756-8722-4-18."/>
<document>
<url value="https://pubmed.ncbi.nlm.nih.gov/21513551/"/>
</document>
<resourceReference>
<identifier>
<system value="https://pubmed.ncbi.nlm.nih.gov"/>
<value value="21513551"/>
<assigner>
<display value="NLM"/>
</assigner>
</identifier>
</resourceReference>
</relatesTo>
<relatesTo>
<type value="cites"/>
<classifier>
<coding>
<system value="http://hl7.org/fhir/citation-artifact-classifier"/>
<code value="D016428"/>
<display value="Journal Article"/>
</coding>
</classifier>
<citation
value="Huang X, Chau CH, Figg WD. Challenges to improved therapeutics for metastatic castrate resistant prostate cancer: from recent successes and failures. J Hematol Oncol. 2012;5:35. doi: 10.1186/1756-8722-5-35."/>
<document>
<url value="https://pubmed.ncbi.nlm.nih.gov/22747660/"/>
</document>
<resourceReference>
<identifier>
<system value="https://pubmed.ncbi.nlm.nih.gov"/>
<value value="22747660"/>
<assigner>
<display value="NLM"/>
</assigner>
</identifier>
</resourceReference>
</relatesTo>
<relatesTo>
<type value="cites"/>
<classifier>
<coding>
<system value="http://hl7.org/fhir/citation-artifact-classifier"/>
<code value="D016428"/>
<display value="Journal Article"/>
</coding>
</classifier>
<citation
value="Dreicer R, Magi-Galluzzi C, Zhou M, Rothaermel J, Reuther A, Ulchaker J, Zippe C, Fergany A, Klein EA. Phase II trial of neoadjuvant docetaxel before radical prostatectomy for locally advanced prostate cancer. Urology. 2004;63(6):1138–1142. doi: 10.1016/j.urology.2004.01.040."/>
<document>
<url value="https://pubmed.ncbi.nlm.nih.gov/15183967/"/>
</document>
<resourceReference>
<identifier>
<system value="https://pubmed.ncbi.nlm.nih.gov"/>
<value value="15183967"/>
<assigner>
<display value="NLM"/>
</assigner>
</identifier>
</resourceReference>
</relatesTo>
<relatesTo>
<type value="cites"/>
<classifier>
<coding>
<system value="http://hl7.org/fhir/citation-artifact-classifier"/>
<code value="D016428"/>
<display value="Journal Article"/>
</coding>
</classifier>
<citation
value="Febbo PG, Richie JP, George DJ, Loda M, Manola J, Shankar S, Barnes AS, Tempany C, Catalona W, Kantoff PW, Oh WK. Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer. Clin Cancer Res. 2005;11(14):5233–5240. doi: 10.1158/1078-0432.CCR-05-0299."/>
<document>
<url value="https://pubmed.ncbi.nlm.nih.gov/16033841/"/>
</document>
<resourceReference>
<identifier>
<system value="https://pubmed.ncbi.nlm.nih.gov"/>
<value value="16033841"/>
<assigner>
<display value="NLM"/>
</assigner>
</identifier>
</resourceReference>
</relatesTo>
<relatesTo>
<type value="cites"/>
<classifier>
<coding>
<system value="http://hl7.org/fhir/citation-artifact-classifier"/>
<code value="D016428"/>
<display value="Journal Article"/>
</coding>
</classifier>
<citation
value="Magi-Galluzzi C, Zhou M, Reuther AM, Dreicer R, Klein EA. Neoadjuvant docetaxel treatment for locally advanced prostate cancer: a clinicopathologic study. Cancer. 2007;110(6):1248–1254. doi: 10.1002/cncr.22897."/>
<document>
<url value="https://pubmed.ncbi.nlm.nih.gov/17674353/"/>
</document>
<resourceReference>
<identifier>
<system value="https://pubmed.ncbi.nlm.nih.gov"/>
<value value="17674353"/>
<assigner>
<display value="NLM"/>
</assigner>
</identifier>
</resourceReference>
</relatesTo>
<relatesTo>
<type value="cites"/>
<classifier>
<coding>
<system value="http://hl7.org/fhir/citation-artifact-classifier"/>
<code value="D016428"/>
<display value="Journal Article"/>
</coding>
</classifier>
<citation
value="Mellado B, Font A, Alcaraz A, Aparicio LA, Veiga FJ, Areal J, Gallardo E, Hannaoui N, Lorenzo JR, Sousa A, Fernandez PL, Gascon P. Phase II trial of short-term neoadjuvant docetaxel and complete androgen blockade in high-risk prostate cancer. Br J Cancer. 2009;101(8):1248–1252. doi: 10.1038/sj.bjc.6605320."/>
<document>
<url value="https://pubmed.ncbi.nlm.nih.gov/19755998/"/>
</document>
<resourceReference>
<identifier>
<system value="https://pubmed.ncbi.nlm.nih.gov"/>
<value value="19755998"/>
<assigner>
<display value="NLM"/>
</assigner>
</identifier>
</resourceReference>
</relatesTo>
<relatesTo>
<type value="cites"/>
<classifier>
<coding>
<system value="http://hl7.org/fhir/citation-artifact-classifier"/>
<code value="D016428"/>
<display value="Journal Article"/>
</coding>
</classifier>
<citation
value="Chi KN, Chin JL, Winquist E, Klotz L, Saad F, Gleave ME. Multicenter phase II study of combined neoadjuvant docetaxel and hormone therapy before radical prostatectomy for patients with high risk localized prostate cancer. J Urol. 2008;180(2):565–570. doi: 10.1016/j.juro.2008.04.012."/>
<document>
<url value="https://pubmed.ncbi.nlm.nih.gov/18554663/"/>
</document>
<resourceReference>
<identifier>
<system value="https://pubmed.ncbi.nlm.nih.gov"/>
<value value="18554663"/>
<assigner>
<display value="NLM"/>
</assigner>
</identifier>
</resourceReference>
</relatesTo>
<relatesTo>
<type value="cites"/>
<classifier>
<coding>
<system value="http://hl7.org/fhir/citation-artifact-classifier"/>
<code value="D016428"/>
<display value="Journal Article"/>
</coding>
</classifier>
<citation
value="Sella A, Zisman A, Kovel S, Yarom N, Leibovici D, Lindner A. Neoadjuvant chemohormonal therapy in poor-prognosis localized prostate cancer. Urology. 2008;71(2):323–327. doi: 10.1016/j.urology.2007.08.060."/>
<document>
<url value="https://pubmed.ncbi.nlm.nih.gov/18308112/"/>
</document>
<resourceReference>
<identifier>
<system value="https://pubmed.ncbi.nlm.nih.gov"/>
<value value="18308112"/>
<assigner>
<display value="NLM"/>
</assigner>
</identifier>
</resourceReference>
</relatesTo>
<relatesTo>
<type value="cites"/>
<classifier>
<coding>
<system value="http://hl7.org/fhir/citation-artifact-classifier"/>
<code value="D016428"/>
<display value="Journal Article"/>
</coding>
</classifier>
<citation
value="Narita S, Tsuchiya N, Kumazawa T, Maita S, Numakura K, Obara T, Tsuruta H, Saito M, Inoue T, Horikawa Y, Satoh S, Nanjyo H, Habuchi T. Short-term clinicopathological outcome of neoadjuvant chemohormonal therapy comprising complete androgen blockade, followed by treatment with docetaxel and estramustine phosphate before radical prostatectomy in Japanese patients with high-risk localized prostate cancer. World J Surg Oncol. 2012;10:1. doi: 10.1186/1477-7819-10-1."/>
<document>
<url value="https://pubmed.ncbi.nlm.nih.gov/22214417/"/>
</document>
<resourceReference>
<identifier>
<system value="https://pubmed.ncbi.nlm.nih.gov"/>
<value value="22214417"/>
<assigner>
<display value="NLM"/>
</assigner>
</identifier>
</resourceReference>
</relatesTo>
<relatesTo>
<type value="cites"/>
<classifier>
<coding>
<system value="http://hl7.org/fhir/citation-artifact-classifier"/>
<code value="D016428"/>
<display value="Journal Article"/>
</coding>
</classifier>
<citation
value="van der Kwast TH, Têtu B, Candas B, Gomez JL, Cusan L, Labrie F. Prolonged neoadjuvant combined androgen blockade leads to a further reduction of prostatic tumor volume: three versus six months of endocrine therapy. Urology. 1999;53(3):523–529. doi: 10.1016/S0090-4295(98)00542-1."/>
<document>
<url value="https://pubmed.ncbi.nlm.nih.gov/10096378/"/>
</document>
<resourceReference>
<identifier>
<system value="https://pubmed.ncbi.nlm.nih.gov"/>
<value value="10096378"/>
<assigner>
<display value="NLM"/>
</assigner>
</identifier>
</resourceReference>
</relatesTo>
<relatesTo>
<type value="cites"/>
<classifier>
<coding>
<system value="http://hl7.org/fhir/citation-artifact-classifier"/>
<code value="D016428"/>
<display value="Journal Article"/>
</coding>
</classifier>
<citation
value="Hu JC, Elkin EP, Pasta DJ, Lubeck DP, Kattan MW, Carroll PR, Litwin MS. Predicting quality of life after radical prostatectomy: results from CaPSURE. J Urol. 2004;171(2 Pt 1):703–708."/>
<document>
<url value="https://pubmed.ncbi.nlm.nih.gov/14713791/"/>
</document>
<resourceReference>
<identifier>
<system value="https://pubmed.ncbi.nlm.nih.gov"/>
<value value="14713791"/>
<assigner>
<display value="NLM"/>
</assigner>
</identifier>
</resourceReference>
</relatesTo>
<relatesTo>
<type value="cites"/>
<classifier>
<coding>
<system value="http://hl7.org/fhir/citation-artifact-classifier"/>
<code value="D016428"/>
<display value="Journal Article"/>
</coding>
</classifier>
<citation
value="Kim WY, Whang YE, Pruthi RS, Baggstrom MQ, Rathmell WK, Rosenman JG, Wallen EM, Goyal LK, Grigson G, Watkins C, Godley PA. Neoadjuvant docetaxel/estramustine prior to radical prostatectomy or external beam radiotherapy in high risk localized prostate cancer: a phase II trial. Urol Oncol. 2011;29(6):608–613. doi: 10.1016/j.urolonc.2009.09.012."/>
<document>
<url value="https://pubmed.ncbi.nlm.nih.gov/20022268/"/>
</document>
<resourceReference>
<identifier>
<system value="https://pubmed.ncbi.nlm.nih.gov"/>
<value value="20022268"/>
<assigner>
<display value="NLM"/>
</assigner>
</identifier>
</resourceReference>
</relatesTo>
<relatesTo>
<type value="cites"/>
<classifier>
<coding>
<system value="http://hl7.org/fhir/citation-artifact-classifier"/>
<code value="D016428"/>
<display value="Journal Article"/>
</coding>
</classifier>
<citation
value="Schulman CC, Debruyne FM, Forster G, Selvaggi FP, Zlotta AR, Witjes WP. 4-year follow-up results of a European prospective randomized study on neoadjuvant hormonal therapy prior to radical prostatectomy in T2-3N0M0 prostate cancer. European Study Group on Neoadjuvant Treatment of Prostate Cancer. Eur Urol. 2000;38(6):706–713. doi: 10.1159/000020366."/>
<document>
<url value="https://pubmed.ncbi.nlm.nih.gov/11111188/"/>
</document>
<resourceReference>
<identifier>
<system value="https://pubmed.ncbi.nlm.nih.gov"/>
<value value="11111188"/>
<assigner>
<display value="NLM"/>
</assigner>
</identifier>
</resourceReference>
</relatesTo>
<relatesTo>
<type value="cites"/>
<classifier>
<coding>
<system value="http://hl7.org/fhir/citation-artifact-classifier"/>
<code value="D016428"/>
<display value="Journal Article"/>
</coding>
</classifier>
<citation
value="Hussain M, Smith DC, El-Rayes BF, Du W, Vaishampayan U, Fontana J, Sakr W, Wood D. Neoadjuvant docetaxel and estramustine chemotherapy in high-risk/locallyadvanced prostate cancer. Urology. 2003;61(4):774–780. doi: 10.1016/S0090-4295(02)02519-0."/>
<document>
<url value="https://pubmed.ncbi.nlm.nih.gov/12670564/"/>
</document>
<resourceReference>
<identifier>
<system value="https://pubmed.ncbi.nlm.nih.gov"/>
<value value="12670564"/>
<assigner>
<display value="NLM"/>
</assigner>
</identifier>
</resourceReference>
</relatesTo>
<relatesTo>
<type value="cites"/>
<classifier>
<coding>
<system value="http://hl7.org/fhir/citation-artifact-classifier"/>
<code value="D016428"/>
<display value="Journal Article"/>
</coding>
</classifier>
<citation
value="Eastham JA, Kelly WK, Grossfeld GD, Small EJ. Cancer and Leukemia Group B (CALGB) 90203: a randomized phase 3 study of radical prostatectomy alone versus estramustine and docetaxel before radical prostatectomy for patients with high-risk localized disease. Urology. 2003;62(Suppl 1):55–62."/>
<document>
<url value="https://pubmed.ncbi.nlm.nih.gov/14747042/"/>
</document>
<resourceReference>
<identifier>
<system value="https://pubmed.ncbi.nlm.nih.gov"/>
<value value="14747042"/>
<assigner>
<display value="NLM"/>
</assigner>
</identifier>
</resourceReference>
</relatesTo>
<relatesTo>
<type value="cites"/>
<classifier>
<coding>
<system value="http://hl7.org/fhir/citation-artifact-classifier"/>
<code value="D016428"/>
<display value="Journal Article"/>
</coding>
</classifier>
<citation
value="D’Amico AV, Chang E, Garnick M, Kantoff P, Jiroutek M, Tempany CM. Assessment of prostate cancer volume using endorectal coil magnetic resonance imaging: a new predictor of tumor response to neoadjuvant androgen suppression therapy. Urology. 1998;51(2):287–292. doi: 10.1016/S0090-4295(97)00610-9."/>
<document>
<url value="https://pubmed.ncbi.nlm.nih.gov/9495713/"/>
</document>
<resourceReference>
<identifier>
<system value="https://pubmed.ncbi.nlm.nih.gov"/>
<value value="9495713"/>
<assigner>
<display value="NLM"/>
</assigner>
</identifier>
</resourceReference>
</relatesTo>
<relatesTo>
<type value="cites"/>
<classifier>
<coding>
<system value="http://hl7.org/fhir/citation-artifact-classifier"/>
<code value="D016428"/>
<display value="Journal Article"/>
</coding>
</classifier>
<citation
value="D’Amico AV, Halabi S, Tempany C, Titelbaum D, Philips GK, Loffredo M, McMahon E, Sanford B, Vogelzang NJ, Small EJ. Cancer and Leukemia Group B. Tumor volume changes on 1.5 tesla endorectal MRI during neoadjuvant androgen suppression therapy for higher-risk prostate cancer and recurrence in men treated using radiation therapy results of the phase II CALGB 9682 study. Int J Radiat Oncol Biol Phys. 2008;71(1):9–15. doi: 10.1016/j.ijrobp.2007.09.033."/>
<document>
<url value="https://pubmed.ncbi.nlm.nih.gov/18037582/"/>
</document>
<resourceReference>
<identifier>
<system value="https://pubmed.ncbi.nlm.nih.gov"/>
<value value="18037582"/>
<assigner>
<display value="NLM"/>
</assigner>
</identifier>
</resourceReference>
</relatesTo>
<relatesTo>
<type value="cites"/>
<classifier>
<coding>
<system value="http://hl7.org/fhir/citation-artifact-classifier"/>
<code value="D016428"/>
<display value="Journal Article"/>
</coding>
</classifier>
<citation
value="Vuky J, Porter C, Isacson C, Vaughan M, Kozlowski P, Picozzi V, Corman J. Phase II trial of neoadjuvant docetaxel and gefitinib followed by radical prostatectomy in patients with high-risk, locally advanced prostate cancer. Cancer. 2009;115(4):784–791. doi: 10.1002/cncr.24092."/>
<document>
<url value="https://pubmed.ncbi.nlm.nih.gov/19130458/"/>
</document>
<resourceReference>
<identifier>
<system value="https://pubmed.ncbi.nlm.nih.gov"/>
<value value="19130458"/>
<assigner>
<display value="NLM"/>
</assigner>
</identifier>
</resourceReference>
</relatesTo>
<relatesTo>
<type value="cites"/>
<classifier>
<coding>
<system value="http://hl7.org/fhir/citation-artifact-classifier"/>
<code value="D016428"/>
<display value="Journal Article"/>
</coding>
</classifier>
<citation
value="Mottet N, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Schmid HP, Van der Kwast T, Wiegel T, Zattoni F, Heidenreich A. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol. 2011;59(4):572–583. doi: 10.1016/j.eururo.2011.01.025."/>
<document>
<url value="https://pubmed.ncbi.nlm.nih.gov/21315502/"/>
</document>
<resourceReference>
<identifier>
<system value="https://pubmed.ncbi.nlm.nih.gov"/>
<value value="21315502"/>
<assigner>
<display value="NLM"/>
</assigner>
</identifier>
</resourceReference>
</relatesTo>
<relatesTo>
<type value="cites"/>
<classifier>
<coding>
<system value="http://hl7.org/fhir/citation-artifact-classifier"/>
<code value="D016428"/>
<display value="Journal Article"/>
</coding>
</classifier>
<citation
value="Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA. Sildenafil Study Group. Oral sildenafil in the treatment of erectile dysfunction. 1998. J Urol. 2002;167(2 Pt 2):1197–1203."/>
<document>
<url value="https://pubmed.ncbi.nlm.nih.gov/11905901/"/>
</document>
<resourceReference>
<identifier>
<system value="https://pubmed.ncbi.nlm.nih.gov"/>
<value value="11905901"/>
<assigner>
<display value="NLM"/>
</assigner>
</identifier>
</resourceReference>
</relatesTo>
<relatesTo>
<type value="cites"/>
<classifier>
<coding>
<system value="http://hl7.org/fhir/citation-artifact-classifier"/>
<code value="D016428"/>
<display value="Journal Article"/>
</coding>
</classifier>
<citation
value="Bubley GJ, Carducci M, Dahut W, Dawson N, Daliani D, Eisenberger M, Figg WD, Freidlin B, Halabi S, Hudes G, Hussain M, Kaplan R, Myers C, Oh W, Petrylak DP, Reed E, Roth B, Sartor O, Scher H, Simons J, Sinibaldi V, Small EJ, Smith MR, Trump DL, Robin V, Wilding G. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol. 1999;17(11):3461–3467."/>
<document>
<url value="https://pubmed.ncbi.nlm.nih.gov/10550143/"/>
</document>
<resourceReference>
<identifier>
<system value="https://pubmed.ncbi.nlm.nih.gov"/>
<value value="10550143"/>
<assigner>
<display value="NLM"/>
</assigner>
</identifier>
</resourceReference>
</relatesTo>
<publicationForm>
<publishedIn>
<type>
<coding>
<system value="http://hl7.org/fhir/published-in-type"/>
<code value="D020492"/>
<display value="Periodical"/>
</coding>
</type>
<identifier>
<type>
<coding>
<system
value="https://www.nlm.nih.gov/bsd/licensee/elements_descriptions.html#issn"/>
<code value="Electronic"/>
<display value="Electronic"/>
</coding>
<text value="Electronic ISSN Type"/>
</type>
<system value="https://portal.issn.org"/>
<value value="1756-8722"/>
</identifier>
<identifier>
<type>
<coding>
<system value="http://terminology.hl7.org/CodeSystem/v2-0203"/>
<code value="XX"/>
<display value="Organization identifier"/>
</coding>
<text value="ISOAbbreviation"/>
</type>
<system
value="https://www.issn.org/services/online-services/access-to-the-ltwa/"/>
<value value="J Hematol Oncol"/>
</identifier>
<identifier>
<type>
<coding>
<system value="http://terminology.hl7.org/CodeSystem/v2-0203"/>
<code value="XX"/>
<display value="Organization identifier"/>
</coding>
<text value="ISSN Linking"/>
</type>
<system
value="https://www.issn.org/understanding-the-issn/assignment-rules/the-issn-l-for-publications-on-multiple-media/"/>
<value value="1756-8722"/>
</identifier>
<identifier>
<type>
<coding>
<system value="http://terminology.hl7.org/CodeSystem/v2-0203"/>
<code value="XX"/>
<display value="Organization identifier"/>
</coding>
<text value="Medline Title Abbreviation"/>
</type>
<system
value="https://www.nlm.nih.gov/tsd/cataloging/contructitleabbre.html"/>
<value value="J Hematol Oncol"/>
</identifier>
<identifier>
<type>
<coding>
<system value="http://terminology.hl7.org/CodeSystem/v2-0203"/>
<code value="XX"/>
<display value="Organization identifier"/>
</coding>
<text value="NLM Unique ID"/>
</type>
<system
value="https://locatorplus.gov/cgi-bin/Pwebrecon.cgi?DB=local"/>
<value value="101468937"/>
</identifier>
<title value="Journal of hematology & oncology"/>
<publisherLocation value="England"/>
</publishedIn>
<citedMedium>
<coding>
<system value="http://hl7.org/fhir/cited-medium"/>
<code value="internet"/>
<display value="Internet"/>
</coding>
</citedMedium>
<volume value="7"/>
<articleDate value="2014-03-05"/>
<publicationDateText value="2014-Mar-05"/>
<language>
<coding>
<system value="urn:ietf:bcp:47"/>
<code value="en"/>
<display value="English"/>
</coding>
</language>
<pageString value="20"/>
</publicationForm>
<publicationForm>
<citedMedium>
<coding>
<system value="http://hl7.org/fhir/cited-medium"/>
<code value="internet-without-issue"/>
<display value="Internet without issue"/>
</coding>
</citedMedium>
<articleDate value="2014-03-05"/>
</publicationForm>
<webLocation>
<classifier>
<coding>
<system value="http://hl7.org/fhir/artifact-url-classifier"/>
<code value="abstract"/>
<display value="Abstract"/>
</coding>
</classifier>
<url value="https://pubmed.ncbi.nlm.nih.gov/24598155/"/>
</webLocation>
<webLocation>
<classifier>
<coding>
<system value="http://hl7.org/fhir/artifact-url-classifier"/>
<code value="doi-based"/>
<display value="DOI Based"/>
</coding>
</classifier>
<url value="https://doi.org/10.1186/1756-8722-7-20"/>
</webLocation>
<classification>
<type>
<coding>
<system
value="http://hl7.org/fhir/cited-artifact-classification-type"/>
<code value="publishing-model"/>
<display value="Publishing Model"/>
<userSelected value="false"/>
</coding>
</type>
<classifier>
<coding>
<system value="http://hl7.org/fhir/citation-artifact-classifier"/>
<code value="Electronic"/>
<display value="Electronic"/>
<userSelected value="false"/>
</coding>
</classifier>
</classification>
<classification>
<type>
<coding>
<system
value="http://hl7.org/fhir/cited-artifact-classification-type"/>
<code value="chemical"/>
<display value="Chemical"/>
<userSelected value="false"/>
</coding>
</type>
<classifier>
<coding>
<system value="https://meshb.nlm.nih.gov/"/>
<code value="D000726"/>
<display value="Androgen Antagonists"/>
<userSelected value="false"/>
</coding>
</classifier>
<classifier>
<coding>
<system value="https://meshb.nlm.nih.gov/"/>
<code value="D043823"/>
<display value="Taxoids"/>
<userSelected value="false"/>
</coding>
</classifier>
<classifier>
<coding>
<system
value="https://www.cas.org/support/documentation/chemical-substances"/>
<code value="15H5577CQD"/>
<userSelected value="false"/>
</coding>
<coding>
<system value="https://meshb.nlm.nih.gov/"/>
<code value="D000077143"/>
<display value="Docetaxel"/>
<userSelected value="false"/>
</coding>
</classifier>
</classification>
<classification>
<type>
<coding>
<system
value="http://hl7.org/fhir/cited-artifact-classification-type"/>
<code value="mesh-heading"/>
<display value="MeSH Heading"/>
</coding>
</type>
<artifactAssessment>
<reference value="#meshHeading0"/>
<type value="ArtifactAssessment"/>
</artifactAssessment>
</classification>
<classification>
<type>
<coding>
<system
value="http://hl7.org/fhir/cited-artifact-classification-type"/>
<code value="publication-type"/>
<display value="Publication Type"/>
</coding>
</type>
<classifier>
<coding>
<system value="https://meshb.nlm.nih.gov/"/>
<code value="D017427"/>
<display value="Clinical Trial, Phase II"/>
<userSelected value="false"/>
</coding>
</classifier>
<classifier>
<coding>
<system value="https://meshb.nlm.nih.gov/"/>
<code value="D016428"/>
<display value="Journal Article"/>
<userSelected value="false"/>
</coding>
</classifier>
</classification>
<classification>
<type>
<coding>
<system
value="http://hl7.org/fhir/cited-artifact-classification-type"/>
<code value="knowledge-artifact-type"/>
<display value="Knowledge Artifact Type"/>
<userSelected value="false"/>
</coding>
</type>
<classifier>
<coding>
<system value="http://hl7.org/fhir/citation-artifact-classifier"/>
<code value="D016428"/>
<display value="Journal Article"/>
<userSelected value="false"/>
</coding>
</classifier>
<artifactAssessment>
<display value="Classifier added by Computable Publishing LLC"/>
</artifactAssessment>
</classification>
<classification>
<type>
<coding>
<system
value="http://hl7.org/fhir/cited-artifact-classification-type"/>
<code value="citation-subset"/>
<display value="Citation Subset"/>
<userSelected value="false"/>
</coding>
</type>
<classifier>
<coding>
<system
value="https://www.nlm.nih.gov/bsd/licensee/elements_descriptions.html#citationsubset"/>
<code value="IM"/>
<display value="IM"/>
<userSelected value="false"/>
</coding>
</classifier>
</classification>
<contributorship>
<complete value="true"/>
<entry>
<contributor>
<reference value="#author0"/>
<type value="Practitioner"/>
<display value="Thalgott M"/>
</contributor>
<forenameInitials value="M"/>
<affiliation>
<display
value="Department of Urology, Klinikum rechts der Isar, Technische Universität München, Ismaninger Str, 22, Munich 81675, Germany. mark.thalgott@lrz.tum.de."/>
</affiliation>
</entry>
<entry>
<contributor>
<reference value="#author1"/>
<type value="Practitioner"/>
<display value="Horn T"/>
</contributor>
<forenameInitials value="T"/>
</entry>
<entry>
<contributor>
<reference value="#author2"/>
<type value="Practitioner"/>
<display value="Heck MM"/>
</contributor>
<forenameInitials value="MM"/>
</entry>
<entry>
<contributor>
<reference value="#author3"/>
<type value="Practitioner"/>
<display value="Maurer T"/>
</contributor>
<forenameInitials value="T"/>
</entry>
<entry>
<contributor>
<reference value="#author4"/>
<type value="Practitioner"/>
<display value="Eiber M"/>
</contributor>
<forenameInitials value="M"/>
</entry>
<entry>
<contributor>
<reference value="#author5"/>
<type value="Practitioner"/>
<display value="Retz M"/>
</contributor>
<forenameInitials value="M"/>
</entry>
<entry>
<contributor>
<reference value="#author6"/>
<type value="Practitioner"/>
<display value="Autenrieth M"/>
</contributor>
<forenameInitials value="M"/>
</entry>
<entry>
<contributor>
<reference value="#author7"/>
<type value="Practitioner"/>
<display value="Herkommer K"/>
</contributor>
<forenameInitials value="K"/>
</entry>
<entry>
<contributor>
<reference value="#author8"/>
<type value="Practitioner"/>
<display value="Krause BJ"/>
</contributor>
<forenameInitials value="BJ"/>
</entry>
<entry>
<contributor>
<reference value="#author9"/>
<type value="Practitioner"/>
<display value="Gschwend JE"/>
</contributor>
<forenameInitials value="JE"/>
</entry>
<entry>
<contributor>
<reference value="#author10"/>
<type value="Practitioner"/>
<display value="Treiber U"/>
</contributor>
<forenameInitials value="U"/>
</entry>
<entry>
<contributor>
<reference value="#author11"/>
<type value="Practitioner"/>
<display value="Kübler HR"/>
</contributor>
<forenameInitials value="HR"/>
</entry>
</contributorship>
</citedArtifact>
</Citation>
IG © 2022+ HL7 International / Clinical Decision Support. Package hl7.fhir.uv.ebm#1.0.0-ballot based on FHIR 5.0.0. Generated 2024-05-16
Links: Table of Contents |
QA Report
| Version History |
|
Propose a change